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8ABSTRACT
The challenge of future stroke therapy is to translate the basic pathophysiological evidence of
ischemic neuronal injury mechanisms into novel neuroprotective therapies either
independently or in combination with thrombolysis. The identification of pivotal molecular
events in ischemic brain tissue is a prerequisite for designing and interpreting therapies that
target them to limiting the progression of brain injury. The inflammatory mediators act on
several pathways in the ischemic brain. It was our goal to describe two potent cytokines and
their receptor behavior in experimental brain ischemia. Also, the activation of the key enzyme
of prostanoid production was investigated at cellular level in infarcted human brains.
Furthermore, we wanted to test how findings from experimental ischemia models translate
into occurrences in human brain infarction.
Based on our experimental data on rat global forebrain ischemia, neurons in areas
selectively vulnerable for delayed neuronal death may be target cells for ischemia-induced
glial interleukin-1β (IL-1β) effects. Sequential expression of the immediate early gene c-fos
and tumor necrosis factor-α (TNF-α) mRNA (messenger ribonucleic acid) supports
participation of c-fos in regulation of TNF-α mRNA expression in striatal and hippocampal
neurons. After global forebrain ischemia, increased neuronal type I TNF receptor (TNFR1)
immunostaining in conjunction with increased immunostaining for TNF-α in
oligodendrocytes suggests signaling to neurons by enhanced oligoglial TNF-α.
Based on our data on human focal ischemic brain infarction, endogenous TNF-α
immunoreactivity is induced bilaterally in multiple neural cell types up until chronic phases of
ischemia. This response shows a partial overlap with TdT-mediated dUTP nick end labeling
(TUNEL)-depicted dying cells during the first days of infarct maturation. Even more
pronounced ischemia-induced cyclooxygenase-2 (COX-2) immunoreactivity was detectable
widely in neural cells, and a topographical evolution of this response evolves throughout
infarct maturation phases from acute to chronic durations of ischemia. Neuronal COX-2
immunoreactivity was detectable also in healthy brain areas, in addition to marked bilateral
immunoreactivity in glial and vascular cells. This response was extended beyond heat shock
protein (HSP72/73) immunoreactivity, which reflects mere cellular stress response.
In sum, the cellular expression of cytokines TNF-α and IL-1β and their signal
transducing receptors is regulated differentially at the level of mRNA and of protein.
Furthermore, inflammatory events described in rodent brains were repeatable in human
infarcted brain with the distinction of more prolonged, multicellular, and bilateral expression
of the mediators investigated.
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ABBREVIATIONS
AA arachidonic acid
AD Alzheimer’s disease
AEC aminoethylcarbazole
AP-1 activator protein-1
ATP adenosine triphosphate
CA1, CA2, CA3/4, DG respective subfields (CA1, CA2, CA3/CA4) and dentate gyrus
of the hippocampal formation
CBF cerebral blood flow
c-fos immediate early gene c-fos
COX-2 cyclooxygenase-2
CSF cerebrospinal fluid
CNS central nervous system
DAB diaminobenzidine
dUTP deoxyuridine-triphosphate
DWI diffusion-weighted magnetic resonance imaging
FITC fluorescein isothiosyanate
GAPDH glyceraldehyde-3-phosphate dehydrogenase
HPA hypothalamic-pituitary-adrenal axis
HSP heat shock protein
kDa kilodalton
ICE interleukin-1 converting enzyme
IGF insulin-like growth factor
IEG immediate early gene
IFMA immunofluorometric assay
IL-1β interleukin-1β
IL-1R interleukin-1 receptor
IL-1RacP IL-1 receptor-accessory protein
I/R ischemia followed by reperfusion
LTP long term potentiation
LPS lipopolysaccharide
MABP mean arterial blood pressure
MCAO middle cerebral artery occlusion (transient or permanent)
mRNA messenger ribonucleic acid
NF-κB transcription factor nuclear factor-kappaB
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NGF nerve growth factor
NMDA glutamate-agonist N-methyl-D-aspartate
NO(S) nitric oxide (synthase)
NSAID non-steroidal anti-inflammatory drug
PET positron emission tomography
PBS phosphate buffered saline
PCR polymerase chain reaction
PG prostaglandin
PKC phosphokinase C
PLA2 phosphoplipase A2
PMNL polymorphonuclear leukocytes
Rt-PA recombinant tissue-plasminogen activator
TBS tris buffered saline
TdT terminal deoxynucleotidyl transferase
TNF-α tumor necrosis factor-α
TNFR tumor necrosis factor receptor; TNFR1=tumor necrosis factor
receptor, type I
TUNEL terminal deoxynucleotidyl transferase (TdT)-mediated
deoxyuridine-triphosphate (dUTP) nick end labeling
TX thromboxane
TxRed Texas Red
XeCT xenon computerized tomography
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INTRODUCTION
In 1847, Virchow introduced the concept that systemic emboli lodging in the
cerebrovasculature and vascular occlusion cause stroke, but the therapeutic implications of
this notion were not fully implemented until more than a century later (reviewed by Norris
and Hachinski, 1991). To date, the only specific drug therapy for acute ischemic stroke is still
thrombolysis with recombinant tissue plasminogen activator (rt-PA) (the National Institutes of
Neurological Disorders and Stroke, NINDS, Stroke study group, 1995). Severe limitations of
this therapy stem from its requirement of early patient hospitalization for acute brain imaging,
experience in interpretation of early infarct signs in the images, and strict inclusion and
exclusion criteria regarding clinical presentation and comorbid diseases. In clinical practice,
only about 5 to 10% of stroke patients are eligible for this treatment (Fisher and
Bogousslavsky, 1998) and estimates are that only 1 patient of seven treated with thrombolysis
within 3 hours from symptom onset will avoid disability or death (Donnan, 1998). This sets
the stage for other treatments, i.e., neuroprotection, for acute stroke, ones  with wider
therapeutic windows and with no requirement of early brain imaging. The future challenge of
stroke therapy is how to translate basic pathophysiologic evidence of ischemic neuronal injury
into novel neuroprotective therapies either independent or in combination with thrombolysis
(Lindsberg et al., 2000).
Technical advances in vascular and brain imaging have been invaluable
understanding stroke pathogenesis. However, much basic pathophysiologic knowledge has
been derived from animal models mimicking human stroke. The further importance of these
models lies in preclinical testing of drugs designed for neuroprotection that ultimately may
improve functional recovery from stroke. Disappointingly, promising results of over a
hundred neuroprotective drugs shown effective in animals have not yet led to success in the
treatment of human stroke (Caplan, 1998, Fisher and Bogousslavsky, 1998, Heiss et al., 1999,
Muir and Grosset, 1999). In order to examine reasons for treatment failures, one must return
to basic pathophysiologic investigations on sequelae of cerebral ischemia both in animal and
human brains. Furthermore, much of the attention has been focused on the processes within
the acute infarct and should be shifted to the entire cerebrum over the whole duration of
infarct maturation, to avoid neglecting phenomena participating in reparative processes and
reorganization of the surviving central nervous tissue.
Spontaneous or drug-induced recanalization of the occluded vessels not only leads to
vital resupply of oxygen to the brain tissue, but also induces what is called reperfusion
damage at the interface between circulating blood cells and the endothelium (Beckman, 1998,
Hallenbeck and Kochanek 1998). Consequences of this interaction include formation of free
radicals, adhesion, and the entry of leukocytes into brain tissue. Besides this primarily
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vasculature-driven inflammatory response, resident brain cells, including neurons and glial
cells, participate in the events that lead to enhancement of the inflammatory processes
(Hallenbeck and Kochanek, 1998). Among potent mediators of the inflammatory response are
cytokines, several of which have been detected in infarcted brain tissue of rodents (Feuerstein
et al., 1998). Interestingly, in rodents pharmacological inhibition of pro-inflammatory
cytokines including tumor necrosis factor-α (TNF-α) (Barone et al., 1997, Dawson et al.,
1996., Nawashiro et al., 1997a, Lavine et al., 1998) and interleukin-1β (IL-1β) (Relton and
Rothwell, 1992, Betz et al., 1995, Garcia et al., 1995, Yamasaki et al., 1995, Relton et al.
1996, Schielke et al., 1998) has led to smaller brain infarcts. Furthermore, antagonists of
cyclo-oxygenase-2 (COX-2), another mediator of inflammation responsible for the production
of vasoactive prostanoids (Baethmann et al., 1989, Farooqui and Horrocks, 1991), reduces
ischemic neuronal damage (Nakagomi et al., 1989, Clemens et al., 1991). COX-2 antagonism
has led to smaller infarct size under conditions of ischemia followed by reperfusion (Chen et
al., 1995, Nogawa et al., 1997) as opposed to a detrimental effect under conditions of
permanent occlusion with no reperfusion (Cole et al., 1993). With the well-tolerated
pharmaceutical agents now at hand to inhibit tumor necrosis factor-α action (Moreland et al.,
1997, Stack et al., 1997) and cyclooxygenase-2 action, it was of interest to further investigate
cytokine responses in cerebral ischemia and to relate changes in inflammatory mediators
detected in human brain infarction to the experimental background.
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REVIEW OF THE LITERATURE
1. STROKE
1.1. Clinical stroke
In the western world, after myocardial infarction and cancer, the third most common
cause of death is stroke. Besides fatality, stroke is the most common cause of disability
leading to dependency, crucial both in economic and in humanitarian terms. In comparison
with all other somatic diseases, stroke care is responsible for the most hospitalization days. In
Finland, about 12 000 people suffer a stroke per year, and the cost rose up to 4,4 billion
Finnish marks in year 1991 (Soinila et al, eds., 2001). About 80% of strokes are ischemic, i.e.,
result from atherothrombosis or an embolus of the cerebral vasculature (Wolf et al., 1998).
Prevention of stroke is promoted by good control of risk factors such as hypertension, atrial
fibrillation, coronary artery disease, diabetes, hypercholesterolemia, cigarette smoking,
obesity, alcohol abuse, and physical inactivity (Benson and Sacco, 2000). The acute care of a
stroke patient includes ensuring ventilation and oxygen saturation, continuous monitoring of
cardiac and hemodynamic parameters, administration of intravenous fluids, and controlled
normothermia and normoglycemia (Hickenbottom and Barsan, 2000).
1.2.  Pathophysiology of acute stroke
The onset of the clinical symptoms of stroke is usually very sudden. The severity of
ischemic tissue damage is dependent on the extent of cerebral blood flow (CBF) reduction,
and particular thresholds exist for various kinds of pathophysiologic tissue events (Hossmann,
1998). The high sensitivity of the brain to blood flow changes is due to its exclusive energy
demand on oxidative glucose metabolism. A decline in blood flow and oxygen supply below
the level needed for mitochondrial respiration leads to anaerobic glycolysis resulting in a
severely impaired energy supply and acidosis of the brain tissue. With declining blood flow,
the functional neuronal activity is affected first, and as ischemia progresses, the metabolic
activity of the cells in maintaining structural integrity becomes suppressed (Hossmann, 1998),
which finally leads to membrane failure and irreversible cell death.
Types of cell death
In general, two morphologically distinct types of cell death are recognizable: Necrosis
as passive degeneration resulting in cellular dissolution when the internal homeostasis
collapses, and apoptosis, meaning active cellular suicide occurring during normal
development and also being triggered by physiological stimuli. Apoptosis may be present
before the depletion of cellular energy supply, and in some cells, new gene expression and
production of apoptosis-associated proteins is essential in the initiation of apoptosis (Wyllie at
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al., 1980). However, the latter claim has been challenged by studies suggesting that all the
proteins needed for apoptosis are always present in most mammalian cells (reviewed by
Steller, 1995).
1) Necrosis. The hallmarks of morphological changes leading to necrosis are at first
reversible cell swelling with blebbing of the cell surface, dilation of the endoplasmic
reticulum, increased mitochondrial density, and flocculation of the nuclear chromatin. This,
often with explosive rapidity, turns into irreversible cell swelling with mitochondrial dilation
that results in rupture of nuclear membranes. Thereafter, the marginated chromatin appears as
small discrete masses before the loss of all basophilia, which leaves only a nuclear “ghost.”
Rupture of other organelle membranes also ensues, and plasma membrane breakdown makes
cell boundaries indistinct. Exudative inflammation develops in the adjoining viable tissue, and
the debris is ingested and degraded by phagocytes (Wyllie et al., 1980, Duvall and Wyllie,
1986, Majno and Joris, 1995).
2) Apoptosis. In apoptosis, the dying cell shrinks and the cytoplasm condenses
without loss of mitochondrial morphology. The nucleus becomes pyknotic and the nuclear
chromatin is packed into smooth masses against the nuclear membrane. These may bud into
processes containing nuclear fragments. The plasma membrane also becomes convoluted so
that the cell is separated into a cluster of membrane-bound segments termed “apoptotic
bodies,” containing either nuclear fragments or both nuclear and often morphologically
normal cytoplasmic organelles like mitochondria. The apoptotic bodies are rapidly ingested
and digested by phagocytes or other adjacent cells (Duvall and Wyllie, 1986, Majno and Joris,
1995). The participation of these “nonprofessional” phagocyting cells seems to be cellular
cannibalism unique to apoptosis and may be an adaptation needed for developmental purposes
in the embryo, in which no fully-matured inflammatory responses are available (Majno and
Joris, 1995). In any case, this post-apoptotic digestion of cell remnants should appropriately
be called secondary necrosis or apoptotic necrosis. In fact, Trump and Berezesky (1995)
suggest apoptosis to have been known to pathologist for decades under terms such as single
cell necrosis (usually affects only scattered cells as opposed to massive necrosis of the tissue),
and shrinkage necrosis, although its total significance was not appreciated earlier; according
to these authors, apoptosis represents a different and prelethal early phase of cell death that
leads into the same final pathway as that seen with other types of toxic cell death This
suggests that apoptotic cell death shares at least some of the cellular death mechanisms
investigated in a necrotic paradigm.
Besides morphological criteria in electron microscopy, apoptosis has been inferred by
gel elecrophoresis of extracted DNA, and more recently by in situ detection of
oligonucleosomal length DNA fragments in histological sections. Two main enzymatic
techniques utilize DNA polymerase (in situ nick translation, ISNT) or terminal transferase
16
(tailing with terminal deoxynucleotidyl transferase, TdT-mediated deoxyuridine-triphosphate
(dUTP) nick end labeling = TUNEL). Both of these methods detect both apoptosis and
necrosis. The latter technique has been proposed to preferentially label apoptotic cells in
comparison to necrotic cells, especially in the early phase of cell death (Gold et al., 1994). In
post-ischemic tissue different phases of cell death coexist, however, and thus the term
TUNEL-labeled dying cells is applied in this text. These morphologic hallmarks of apoptosis
have been identified in ischemic brains, and furthermore, in experimental models of cerebral
ischemia, protection of injured neurons by protein synthesis inhibitors has led to vivid
investigation of the role of apoptotic cell death also in cerebral ischemia (reviewed by
Charriaut-Marlangue and Ben-Ari, 1998). The caspases, a class of cysteine proteases that
serve as the executioners of apoptosis, are studied intensively in stroke and neurodegenerative
diseases (reviewed in Schulz et al., 1999). Interestingly, caspase activation is prominent in
mild ischemic injury and in the area surrounding the infarction core in contrast to the mostly
necrotic cells in the core (Schulz et al., 1999). In line with these findings, a mild insult with
neuro(excito)toxic agents such as glutamate-agonist N-methyl-D-aspartate (NMDA) or nitric
oxide/superoxide results predominantly in neuronal apoptosis, whereas more intense exposure
to these agents resulted in necrotic cell damage (Bonfoco et al., 1995). MacManus and
Buchan (2000) have suggested that apoptosis and necrosis represent two poles of a
continuum. Position on this continuum would be modified by ischemia intensity, the
consequent availability of adenosine triphosphate (ATP) and new protein synthesis, and age
and context of the neuron (MacManus and Buchan, 2000). Moreover, the endonucleases that
fragment the DNA backbone of the dying cell in the ischemic brain are suggested to differ
from those of classical apoptosis, while the resulting DNA fragments are atypically staggered
instead of being blunt-ended (MacManus et al., 1999).
Metabolic disturbances
As reviewed by Siesjö (1992a), ischemia at a higher CBF threshold of around (50 to)
25% of normal flow leads to compromised electrical functions whereas deeper ischemia with
values below 20 to 15% of normal CBF causes membrane failure. The CBF range between
these thresholds corresponds to a cerebral cortex that is functionally silent but structurally
intact. In focal ischemia, all CBF values below 40 to 50% but above the threshold for
structural integrity define a periinfarct area called a penumbra between the necrotic infarct
core and the normally perfused brain, making it a tempting target for CBF restoration by
thrombolysis or neuroprotective therapy (Figure 1). Thus the penumbra is not solely a
topographic locus, but a dynamic process. The penumbra evolves over time because of the
ensuing intermittent or sustained high metabolic demand of the periinfarct tissue (and hence
the heightened energy demand) that is uncoupled from a proportionate increase in local CBF
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due to blood flow obstruction and inadequate collateral supply (Ginsberg and Pulsinelli,
1994). The reason for the expansion of tissue injury into the penumbra zone has been
suggested to be the occurrence of the so-called periinfarct spreading depression-like
depolarizations (Hossmann, 1994), a phenomenon not confirmed in human brain (Dirnagl et
al., 1999). The cells in the penumbra depolarize due to the shortage of energy supply, and the
release of glutamate and K+. The cells are able to repolarize, but only at the expense of further
energy consumption (Dirnagl et al., 1999).
Visualization of the theoretically salvageable area of the penumbra is of great interest.
Variable attempts utilizing imaging techniques like positron emission tomography (PET) (as
in Heiss et al., 1992) or diffusion-weighted magnetic resonance imaging (DWI) (Baird and
Warach, 1998) as well as performing post-mortem histological stainings in experimental
material (Hossmann, 1998) have been applied to characterize the penumbra. In clinical
ischemic stroke, only a narrow if any penumbra has been detectable by Xenon computerized
tomography (XeCT) (Kaufmann et al., 1999). Another recent study utilizing the PET
technique showed that the brain compartment of critical hypoperfusion with blood flow less
than 12 ml/100 g per minute accounted for about 70% of the final infarct size, while
penumbral tissue (18%) and initially sufficiently perfused tissue (12%) were responsible for
the rest (Heiss et al., 1999). This is clearly different from a larger penumbra amenable to
therapeutic approaches in rodent models of focal ischemia (Ginsberg et al., 1999). The critical
need for identification of the penumbra in the human ischemic brain is underscored in the
planning and interpreting of clinical stroke trials (Heiss et al., 1999, Muir and Grosset, 1999).
Core
Penumbra
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Figure 1. Brain infarct topography. Schematic depiction of rat brain after middle cerebral artery
occlusion showing hypothetically the infarct core (gray area) and functionally silent but structurally
intact cortical periinfarct area called the penumbra (diagonal lines). The penumbra is a target for
thrombolysis (reperfusion) and neuroprotective treatment in order to limit the extent of ischemic brain
injury. The identification of the penumbra is of critical importance in both the planning and the
interpretation of stroke treatment. The level of the brain section is + 0.70 mm from the Bregma
(modified from G Paxinos and C Watson: The rat brain in stereotaxic coordinates, 2nd Edition, San
Diego, Academic Press, 1986 and from Hossmann, 1994).
A continuum of viability thresholds can be identified in the metabolic disturbances
during cerebral ischemia that proceed, in the order of their sensitivity to reduced CBF, as
follows: Protein synthesis is inhibited first, followed by suppression of mRNA synthesis. At
this level, anaerobic glycolysis is stimulated and leads to lactic acidosis. Breakdown of energy
state, e.g., cessation of ATP production ensues at even lower blood flow values, and finally
anoxic depolarization of cell membranes leads to influx of calcium (Ca2+) along with
dysregulation of other ion transients as well (Hossmann, 1998). These changes occur during
the early phase of brain infarct maturation, which is responsible for the most significant loss
of tissue also in humans (Heiss et al., 1999), although the cascade of molecular and
biochemical mechanisms still cannot be assessed in patients (Heiss, 2000) (Figure 2).
Figure 2. Schematic diagram of spatial extent (Y-axis) and temporal course (X-axis) of
development of ischemic brain damage. Rapid effects of flow disturbance cause the bulk of the final
infarct, while secondary and delayed effects count for relatively little additional damage (Modified
from Heiss et al., 1999).
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Increased intracellular Ca 2+
The central role of increased intracellular Ca 2+ in ischemic cell death is underscored
by the statement of Kristián and Siesjö (1998) that calcium is one of the triggers involved in
ischemic cell death, regardless of the precise underlying mechanism (Figure 2). The source of
increased intracellular free cytosolic Ca 2+ is not only the extracellular space; Ca 2+ is also
released from intracellular stores such as endoplasmic reticulum (ER), from less well
characterized calciosomes, and from mitochondria during the energy-compromised state
(Siesjö et al., 1999). Once the elevation of intracellular Ca 2+ reaches non-physiological
levels, a host of potentially harmful calcium-dependent enzymes are activated. These include
phospholipases (e.g. phospolipase A2) responsible for the liberation of cell membrane
phospolipids. Degradative enzymes such as proteases and endonucleases fuel free radical
production as does activation of inducible nitric oxide synthase (iNOS) (Kristián and Siesjö et
al., 1998).
Increased intracellular Ca2+ also activates kinases like calcium-dependent protein
kinase C (cPKC), as well as Ca2+/calmodulin-dependent protein kinase II, which in turn,
among other functions, enhance neurotransmitter release and open ion-channels, thus
modulating neurotransmitter receptor activity (reviewed by Wieloch and Kamme, 1998). In
general, protein kinases are enzymes that phosphorylate proteins at the expense of ATP. The
resulting conformational change modifies the target protein functions. Protein
phosphorylation is suggested to regulate a wide array of intracellular processes. Thus the
kinase-regulated balance between gene expression that either promotes cellular protection and
repair (neurotrophic signaling) or that leads to an increase in detrimental factors is perceived
as critical in the fate of the cell (Wieloch and Kamme, 1998).
Neuron-specific cell death due to influx of Ca2+ resulting from ischemia-induced
excessive liberation of excitatory amino acids like glutamate is termed excitotoxic cell death.
Ca2+ enters post-synaptic neurons through Ca2+ channels on the cell surface which are either
1) voltage-gated channels (VOCs) activated by depolarization or 2) agonist-operated
(receptor-gated) channels opened by agonists such as glutamate and aspartate, or 3)
capacitative Ca2+ entry channels (store-operated channels) activated by depletion of
intracellular Ca2+ stores (Meldolesi et al., 1991). The receptor-gated channels include N-
methyl-D-aspartate (NMDA), kainate (low and high affinity), and amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) channels called ionotropic receptors, and
quisqualate, which is not linked to an ion channel and is thus called an metabotropic receptor
(Macdonald and Stoodley, 1998).
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Altered gene expression
During cerebral ischemia, excessive glutamate release leads to increased intracellular
Ca2+ levels that consequently induce protein kinases like PKC These then phosphorylate DNA
binding sites on the promoter regions of so-called immediate-early genes (IEGs) (Morgan and
Curran, 1986, reviewed by Akins et al., 1996). The activation of an IEG called c-fos is one of
the earliest transcriptional events to follow neuronal activation occurring as soon as 30
minutes after reperfusion (Morgan et al., 1987, Hossmann and Wiessner, 1997). C-fos gene
induction does not require prior protein synthesis and it is rapidly induced by brain ischemia
as well as neuronal activation (Akins et al., 1996, Honkaniemi and Sharp, 1996). The Fos
protein associates with another IEG product, namely the Jun protein. The formed heterodimer
regulates the transcription of late-response genes that carry the activator protein-1 (AP-1)
consensus sequence and thus leads to long-term alterations in gene expression and in cell
phenotype (Akins et al., 1996). Continuous expression of c-fos gene precedes programmed
cell death in the CNS of transgenic mice (Smeyne et al., 1993) and, for example, in mice
lacking c-fos retinal apoptosis was virtually absent (Hafezi et al., 1997). In ischemic brain
tissue, prolonged c-fos expression has been proposed as a proximal step in the demise of
vulnerable hippocampal neurons (Jørgensen et al., 1989, Wessel et al., 1991, Akins et al.,
1996, Honkaniemi and Sharp, 1996).
Another class of genes activated early during ischemia is the heat shock proteins
(HSPs) that behave during ischemia in a manner different from that of c-fos. HSPs are not
induced by physiological stimuli, but their mRNAs are readily expressed within 1 h in cells
exposed to different types of stress including heat, a property that has inspired the name for
this class of stress-response genes. HSPs are suggested to act as molecular chaperones that
stabilize the conformation of both normal and denatured proteins so they can maintain and
acquire proper functional integrity (Kogure et al., 1997). HSP70 (also called HSP72) is the
major stress-inducible HSP. Other HSPs induced during cerebral ischemia include ubiquitin,
HSP27, HSP47, HSP60, glucose responsive protein 75 (GRP75), GRP78, and glucose
transporter (GLUT-1). In addition, heat shock cognate protein HSC70 is suggested to play a
role in ischemic preconditioning (tolerance), and HSP90 regulates the expression of HSP70
(Sharp and Massa, 1999). The HSP70 protein induction correlates with duration of cerebral
ischemia and is expressed first in the most ischemia-sensitive neurons, followed by glial cells,
and lastly, by endothelial cells. Moreover, with increasing ischemia severity, the blockade of
transcription and translation of the hsp70 gene occurs in the same order. Thus, moderate
ischemia induces HSP70 protein in neurons that will not die due to the insult but induces none
in those that will eventually be lost; a severe ischemia induces HSP70 protein only in the most
resistant capillary endothelial cells, not in the neuronal or glial cells of the ischemic region
(Sharp et al., 1993, Lindsberg et al., 1996a). This possible cell survival marker has also been
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suggested to characterize the salvageable neuronal cells in the penumbra (Kinouchi et al.,
1993) a view supported also by the lack of colocalization of HSP70-positive and TUNEL-
labeled cells after focal and global ischemia (Sharp et al., 1997). On the other hand, the role
of HSP proteins in neuronal survival has been challenged by their presence in hippocampal
cells destined to die after global ischemia (Simon et al., 1991). Recently, protection of
hippocampal neurons from focal ischemia was shown in HSP70 transgenic mice (Rajdev et
al., 2000). Furthermore, in normal rat brain, HSP70 gene transfer by a viral vector protected
transfected neurons from ischemic damage (reviewed by Sapolsky and Steinberg, 1999). In
sum, the HSP response is dynamic and exists early in injured cells in brain areas with
topographical correlation with severity of the insult (Simon et al., 1991, Sharp et al., 1993).
Because HSP response is evident both in cells that survive and in those destined to die (Yee et
al., 1993), other factors may be decisive in the ultimate fate of these cells (Figure 3).
Cytokines, potent enhancers of inflammation, are secreted by activated leukocytes
entering the brain after 12 hours of infarction (see section 4; Hallenbeck and Kochanek, 1998,
Lindsberg et al., 1996b). Moreover, resident brain cells including neurons and glial and
endothelial cells show peak cytokine protein expression already after 6 to 12 hours in
ischemic rodent brain (Feuerstein et al., 1998) and, cytokines thus represent another class of
genes with altered expression as a response to ischemia.
Changes in gene expression may initiate apoptosis or other detrimental processes.
Altered gene expression due to ischemia, “ischemic gene expression,” is now a field of
growing interest in pathophysiological and therapeutic brain research (Akins et al., 1996).
Figure 3 schematizes some alterations of gene expression due to cerebral ischemia, and Figure
4 summarizes the key events in glutamate-mediated ischemic cell death/excitotoxicity.
Figure 3. Altered gene expression in brain ischemia. The temporal course of partially overlapping,
altered gene expression of suggested mediators of ischemic cell death. Abbreviations: IEG = immediate
early gene, hsp = heat shock protein gene, TUNEL = TdT-mediated dUTP nick end labeling depicting
DNA fragmentation. Positioning of TUNEL-labeling indicates overlap in detection of both necrotic and
apoptotic cells.
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Figure 4. Glutamate-mediated ischemic cell death. The neuron in the upper left corner represents a
presynaptic neuron, and events occurring at the postsynaptic neuron are depicted in the center.
Numbering refers to the theoretical order of sequence of events according to their sensitivity to reduced
CBF. In short, the neuronal vulnerability to ischemia may be related to increased intracellular Ca2+,
infarction is due to acidosis and free radicals, and reperfusion damage results from inflammatory
mediators involving increased intracellular Ca2+, free radicals, and lipid mediators (Siesjö, 1992a and b,
Macdonald and Stoodley, 1998). Repetitive periinfarct depolarizations result from the shortage of
energy, and release of K+ and glutamate and may lead to larger infarction (Modified from Dirnagl et
al., 1999).
Reperfusion damage
Successful treatment with thrombolysis or spontaneous recanalization of the occluded
vessel leads to re-oxygenation of the ischemic brain tissue but it also gives rise to formation
of oxygen free radicals and an influx of inflammatory cells (Beckman 1998, Hallenbeck and
Kochanek, 1998). These events are the hallmarks of reperfusion injury, which largely stems
from the interplay between endothelial cells and normal blood components upon the
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resurgence of oxygen, of metabolism, and of circulating factors of immune surveillance.
Under normal circumstances, the endothelium is an anti-adhesive and anti-thrombotic organ.
Ischemia followed by reperfusion (I/R) induces the endothelium to express adhesion
molecules and chemotactic factors. This transformation attracts and activates platelets and
neutrophils to adhere to the endothelium and the latter to emigrate into the brain parenchyma
in large quantities (Hallenbeck and Kochanek, 1998, Lindsberg et al., 1996b). The capillary
blood flow is impaired by plugging with large neutrophils, which also secrete proteolytic
enzymes and cytokines due to activation (Hallenbeck and Kochanek, 1998). Cell membrane
lipids are broken down by phospholipase A2 (PLA2) activity to release arachidonic acid (AA).
Increased AA metabolism leads to formation of vasoactive, pro-inflammatory eicosanoids
(prostaglandins and thromboxanes) and leukotrienes, and of oxygen free radicals by the
enzymatic activity of cyclooxygenase-2 (COX-2) and lipoxygenase (Figure 5) (Farooqui and
Horrocks, 1991). PLA2 activity also generates lysophospholipids. Free radicals and
inflammatory mediators, along with prostanoids, contribute to the breakdown of the blood-
brain barrier, leading to edema (Macdonald and Stoodley, 1998). Brain edema in turn
aggravates the ischemic injury through increased intracranial pressure by causing local
compression of the microcirculation. Ischemic brain infarction may accumulate fluid and cell
infiltration to become a space-occupying focal lesion, which can dislocate parts of the brain,
leading to herniations often associated with fatal outcome. This occurs typically during the
first day of stroke in rodents and within three days in humans (Bounds et al., 1981).
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Figure 5. Generation of prostanoids from cell membrane lipid-derived arachidonic acid and their
roles in inflammation. Abbreviations: Lyso-PL = lysophospholipid, PAF = platelet-activating factor,
PLA2 = phospholipase A2, 5-HPETE = 5-hydroperoxy eicosatetraenoic acid, HETE = hydroxy
eicosatetraenoic acid. Flow chart modified from: Inflammation and Repair. Basic Pathology, IV
Edition, Robbins SL and V Kumar, (Eds.), WB Saunders Company, Philadelphia, PA, USA, 1987, pp
28-61 and from Bonventre JV, 1997.
It should be noted, that inflammation is evident also without reperfusion (Lyons et al.,
2000) and that not all aspects of inflammation are necessarily detrimental in post-ischemic
tissue. For example, inflammation may mediate important remodeling and repair processes
such as gliosis, removal of damaged tissue, stimulation of neovascular proliferation, and
improved neuronal plasticity (reviewed in Feuerstein et al., 1994).
Reorganization of neural tissue
The functional recovery seen in stroke patients during the first post-ischemic days
may result from recovery of injured tissue but is more likely due to compensation by brain
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areas surviving the ischemic insult (Rose et al., 1993). Various possible mechanisms have
been discussed as responsible for this functional improvement, including resolution of brain
edema, absorption of necrotic tissue, and disappearance of the remote functional depression
called “diaschisis.” Recent data suggest that the adult brain retains a capacity for plasticity
and functional reorganization (Johansson et al., 1997). At the time of functional recovery,
many genes are induced regulating the trophic effects that govern neuronal growth, re-
establishment of the lost synaptic connections (sprouting), and synapse function (Comelli et
al., 1993, Yamada et al., 1997, Nikolich, 1998). These neurotrophic mediators include
neurotrophins such as brain-derived neurotrophic factor (BDNF; Saarelainen et al., 2000),
glial cell line-derived neurotrophic factor, ciliary neurotrophic factor, fibroblast growth
factors, insulin-like growth factors, and transforming growth factors, among others (Nikolich,
1998). For example, a growth factor used to improve neuronal survival, basic fibroblast
growth factor (bFGF), has been shown to reduce infarct size acutely without an effect on CBF
(Tatlisumak et al., 1996) and to improve functional outcome in rats treated chronically for
several weeks without an effect on infarct size (Kawamata et al., 1996).
In a series of studies appreciating these recovery phenomena, Barbro Johansson and
coworkers have shown, in rats, that housing in an enriched environment facilitated functional
recovery as opposed to recovery a in normal environment (Johansson and Ohlsson, 1996).
Improved functional outcome ensued even after a delayed transfer to an enriched environment
(Johansson, 1996). In rats recovering from a unilateral electrical lesion to the sensorimotor
area, dendritic overgrowth was detectable in the hemisphere contralateral to the lesion, and
moreover, overgrowth was dependent on uninhibited use of the intact limb during the first
two weeks (Jones and Schallert, 1994). Such neuronal growth was not achieved solely by
contralateral lesioning or with overuse of one limb without lesioning. This indicates that early
after brain damage there may be a period during which marked structural changes in neural
circuitry can occur in the presence of adequate behavioral demand, which makes it a period
suitable for rehabilitative approaches in the clinical setting.
Diaschisis, first described by von Monakow in 1914, entails functional and metabolic
perturbations in brain structures remote from the site of focal brain damage. Neuroimaging
has revealed widespread metabolic changes not only involving the affected cerebral
hemisphere but also extending into brain areas supplied by contralateral and cerebellar
arteries (Feeney and Baron, 1986). It has been speculated that, early after stroke, diaschisis in
the contralesional hemisphere does not participate in recovery (Iglesias et al., 1996, Mimura
et al., 1998) but in the subacute and chronic phase, diaschitic phenomena may be participants
in active relearning of lost brain functions (Pantano et al., 1996, Seitz et al., 1999). During the
chronic phase, reorganization of functional circuits leading to expansion of local cerebral
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activation territories and recruitment of parallel projecting cortical areas in the ipsilateral and
contralateral hemispheres may be responsible for functional recovery (Seitz et al., 1999).
2. ANIMAL STROKE MODELS
In view of the complexity of human ischemic stroke: variability in lesion size and
location, differing genetic predisposition, underlying chronic diseases such as generalized
atherosclerosis, and the presence of other associated long-standing risk factors like
hypertension, diabetes, and smoking, one realizes that study of the pathophysiological effect
of single factors requires the utilization of relevant animal models. Experiments with
standardized physiological variables are needed to achieve reproducible ischemic insults and
to derive statistically valid conclusions (Ginsberg, 1996). Results obtained under ideal
experimental conditions can be used to screen for the most interesting pathophysiological
and/or therapeutic phenomena to be eventually tested in humans. If suggested to be effective
by animal experiments, careful pilot studies in stroke patients are then needed to determine
the safety, maximal tolerated doses, side-effects, and preliminary efficacy estimates of a given
pharmaceutical compound (Hachinski, 1996, Grotta, 1996).
The most widely used models of ischemic brain injury employ rodents because of
their many advantages in comparison to larger species like rabbits, cats, dogs, or subhuman
primates. Small-animal models mean lower cost, easier physiological monitoring, better
reproducibility of ischemic lesions, easier replication of the studies, and are ethically less
burdened (Ginsberg, 1996).
The supply areas of the anterior cerebral artery (ACA), posterior cerebral artery
(PCA), and middle cerebral artery (MCA) in rats are analogous to those in humans (Coyle,
1975). However, in rats, the PCA arises from the proximal intracranial portion of the internal
carotid artery (ICA), whereas in human it most commonly arises from basilar artery. In the
rat, the posterior communicating artery connects the terminal cerebellar branch of the basilar
artery with the PCA. The blood supply to the thalamus and basal ganglia is also similar to that
in humans (Rieke et al., 1981).
In the rodent models of cerebral ischemia, either focal or global ischemic insults are
induced. Table 1 outlines the major models.
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Table 1. Rodent models of cerebral ischemia.
1. Focal ischemia
A) Middle cerebral artery occlusion in rats (MCAO), mimicking clinical condition of thromboembolic
stroke
Proximal MCAO Distal MCAO
Permanent
- by electro-
coagulation
(plus surgical
section)
Temporary
- by microclip
Permanent or
temporary
- by intra-
luminal suture
Permanent or
temporary
With or
without
ipsilateral and
/or
contralateral
carotid artery
occlusions
Photochemical
distal MCAO
B) Other approaches to occlude MCA
- Autologous or heterologous clot or carbon microsphere embolism models
- Vasoconstrictive MCAO by local application of endothelin-1
- Focal ischemia in spontaneously hypertensive rats (SHR) or in spontaneously hypertensive – stroke-
prone rats (SHRSP), with the largest and most reproducible cortical infarcts. The latter strain develops
strokes spontaneously. Both are less amenable to neuroprotection than other strains.
- Models adapted to mice
- Models adapted to the Mongolian gerbil, with respective smaller animal size and the lack of a
posterior communicating artery
2. Transient global ischemia in rats;
“cardiac arrest” type brain insult.
A) Two-vessel occlusion:
Bilateral carotid occlusion plus hypotension.
Especially suitable for chronic survival studies.
Allows brain stem blood flow; no need for
intensive care measures during reperfusion.
Four-vessel occlusion:
bilateral carotid artery occlusions with prior
vertebral artery electrocoagulation. Allows use of
awake rats. Brain stem ischemia and seizure
incidence high.
B) Gerbil-bilateral common carotid artery occlusion
C) Other miscellaneous (historical) models of transient forebrain ischemia
- Bilateral forebrain compression by intracisternal infusion of artificial CSF
- Graded unilateral hemispheral ischemia: unilateral carotid occlusion plus elevated CSF pressure
- Neck tourniquet: high pressures inflated around neck with blood withdrawal
- Decapitation
- Percutaneous intrathoracic occlusion of the great vessels; cardiac arrest equivalent
- Levine preparation of hypoxia-ischemia (plus modifications): unilateral carotid occlusion followed by
gradual exposure to hypoxia
Modified from Ginsberg and Busto, 1998.
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Mechanisms of cell death after global ischemia
A characteristic of global forebrain ischemia is that the effects of ischemia of short
duration are usually confined to the neuronal population (Kristián and Siesjö, 1998). Five to
12 minutes of global cerebral ischemia leads to extensive injury to pyramidal neurons in all
subsectors of area CA1 of the hippocampus, and death characteristically follows in days.
Prolonging the insult to 20 minutes leads to histopathologic changes also in the dorsolateral
caudoputamen and longer periods of ischemia damage also to the neocortex (Smith et al.,
1984b, reviewed in Ginsberg and Busto, 1998). Glial cells in these sensitive areas are more
resistant to ischemia. This variable vulnerability to cell death was first described by Igor
Klatzo's group and it was called maturation phenomenon (Ito et al., 1975). Later, Kirino and
coworkers (1982) called it selective neuronal death or delayed neuronal death in rodent brains
after global cerebral ischemia. A phenomenon like this was later confirmed also in the human
brain after cardiac arrest (Petito et al., 1987, Horn and Schlote, 1992).
Enormous research interest with high therapeutic expectations has been invested in
the phenomenon of delayed neuronal death to gain insight into the sensitivity of neurons to
injury. Because of the apparent lack of vascular distribution to the selectively vulnerable
zones, several mechanisms have been proposed to underlie this extraordinary pattern of cell
death, but controversy still remains as to the direct causal role of many suggested factors.
Most of the hypotheses have derived support from intervention studies in which delayed
neuronal death has been interrupted either by reducing the brain’s metabolic and functional
activity by hypothermia or anesthesia, or by interruption of the excitatory input either by
excitatory receptor blockade or by calcium-channel blockers. Various mechanisms have been
speculated upon responsible for the neuroprotection either as independent effectors or
mediators of other neuroprotective mechanisms such as hypothermia. These mechanisms
include suppression of the stress response, preservation of protein kinase C activity, and
stimulation of growth-factor-mediated neuroprotection (reviewed in Mies, 1998). The failure
of the protein-synthesizing machinery to recover has also been suggested to represent a
pathophysiologic aspect of cell injury in the CNS. This may also be applicable to the delayed
neuronal death with persistently disturbed protein synthesis in the vulnerable areas (Thilmann
et al., 1986, Mies, 1998). Furthermore, impaired mitochondrial DNA expression can
compromise ATP production in the CA1 neurons, which has been hypothesized as of crucial
importance in the necrotic death of these cells short of the ATP necessary for recovering
normal function (Abe et al., 1995). On the other hand, biochemical and morphological data
suggest delayed neuronal death to represent a form of programmed cell death, apoptosis
(Scheiber and Baudry, 1995).
Extending from the hypotheses derived from descriptive studies of delayed neuronal
cell death, recent interventions in genetically engineered mice have re-addressed the issue. In
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global ischemia, hippocampal damage has been ameliorated in transgenic mice
overexpressing BCL-2, an inhibitor of apoptosis (Kitagawa et al., 1998). In support of the role
of free radicals in the pathophysiology of delayed ischemic death, overexpressing antioxidant
agents such as superoxide dismutase (SOD1) ( = CuZn-superoxide dismutase) in transgenic
mice protects vulnerable neurons from ischemic damage (Murakami et al., 1997, Chan et al.,
1998). Yet, at this point, it is not clear which factors determine the irreversible fate of the
dying cells.
3. INFLAMMATION IN CEREBRAL ISCHEMIA
The extent of brain damage caused by the insult is ultimately determined by a
combination of ischemic cell necrosis and detrimental host response. The classic assumption
of the brain as an “immune-privileged” organ isolated from immune responses mediated by
humoral factors or circulating cells has been discarded. Evidence has accumulated during the
last decade on the capability of the CNS to express a well-defined inflammatory reaction to a
variety of insults including trauma, ischemia, transplantation, infections, and toxins, as well as
neurodegeneration (Feuerstein et al., 1998). Many aspects of this centrally-derived
inflammatory response to same extent parallel the nature of the reaction in the periphery, but
the existence of the blood-brain barrier and specific resident cells of the brain parenchyma
offer characteristics unique to the CNS
3.1. Reperfusion injury
Tissue reoxygenation upon return of blood flow is crucial and beneficial but also
incites, paradoxically, harmful effects resulting from the interplay between the endothelial
cells and normal blood components, which is termed reperfusion injury (Hallenbeck and
Dutka, 1990). Although the vascular endothelium was long to be held a passive bystander
during ischemia, it has recently become clear that it is capable both of detecting low oxygen
tension and of responding to it by secreting factors to the circulation. Events both within the
microvascular lumen and in the immediate surrounding tissue are involved in the activation of
the endothelium. As reviewed by Hallenbeck and Dutka (1990), under normal circumstances,
the endothelium is an anticoagulant and antiadhesive surface, and one major cause for these
properties is the thrombomodulin-protein C-protein S-system that stabilizes thrombin and
inactivates factors V and VIII and plasminogen activator inhibitor type I (PAI-1).
Furthermore, tissue plasminogen activator is released from the endothelium, which also
produces a tissue factor pathway inhibitor (TFPI) and heparin-like molecules. Furthermore,
adenosine, with its platelet inhibiting and vasodilating properties, and a general protease
inhibitor, α2-macroglobulin, are present on the endothelial surface (reviewed by Hallenbeck
and Kochanek, 1998).
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Transformation of the endothelium
A “Jekyll to Hyde” transformation of the endothelium renders it prothrombotic and
proinflammatory in response to various mediators induced by ischemic insult among other
causes. This transformation results in part from the increased tissue factor (TF) expression
activating the extrinsic pathway of blood coagulation. Thromboxane A2 has vasoconstricting
and platelet aggregatory effects that are antagonized by prostacyclin. A change in their ratio
as a result of endothelial lipooxygenase activation leads to the release of leukotrienes
enhancing chemotaxis for leukocytes and to vasoconstriction and to increased vascular
permeability (Hallenbeck and Kochanek, 1998). Other chemical mediators released from the
endothelium and controlling the vascular tone include endothelins, endothelin-1 being the
most potent known vasoconstrictor. On the other hand, injury-driven release of nitric oxide
(NO), formerly called endothelium-derived relaxing factor, leads to vasodilation (Hallenbeck
and Kochanek, 1998).
Free radicals
Cerebral nitric oxide (NO) has divergent roles as neuronal messenger molecule and
oxygen free radical. In post-ischemic brain, beneficial properties of NO produced by
endothelial nitric oxide synthase (eNOS) are contrasted by neurotoxic nitric oxide generation
by ischemic neurons within 10 minutes (nNOS). Neuronally-derived NO is itself an oxygen
free radical and generates other potent radicals such as peroxynitrate (ONOO-) together with
another free radical superoxide anion (O2-) (Samdani et al., 1997, Fellman and Raivio, 1997).
The superoxide anion is speculated to be derived from the enzymatic actions of the xanthine
oxidase system and also from cyclooxygenase/hydroperoxidase reactions as a by-product of
the prostaglandin synthesis (Hallenbeck and Kochanek, 1998). Inducible NOS (iNOS)
contributes to late neuronal injury after 12 h to days (Samdani et al., 1997). Free radical
formation aggravates brain injury by initiating lipid peroxidation in cell membranes and by
damaging key intracellular organelles. Free radicals also modulate signal transduction by
activation of nuclear transcription factors activator protein-1 (AP-1) and nuclear factor kappa-
B (NF-κB) (Shristava and Aggarwal, 1999) that, in turn, modulate expression of factors
associated with cellular proliferation and inflammatory responses.
Expression of surface receptors for leukocyte binding
Expression of surface receptors for leukocyte binding increases during reperfusion
following ischemia; these include the endothelium-leukocyte adhesion molecule-1 (ELAM-1;
E-selectin) and the P-selectin which is expressed both on endothelial cells and platelets. These
receptors are suggested to contribute to the leukocyte rolling that precedes tighter adhesion
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mediated through integrins such as intercellular adhesion molecule-1 (ICAM-1). The peak
expression of mRNA for these adhesion molecules in rodent brain requires 4 to 6 hours after
ischemia with reperfusion (Feuerstein et al., 1998 and Hallenbeck and Kochanek, 1998).
Adhesion to these molecules is a prerequisite for the entry of leukocytes into the brain
parenchyma; additionally, small capillaries can be plugged by the adhering leukocytes,
possibly leading to “no-reflow” phenomenon (Hallenbeck and Dutka, 1990, del Zoppo et al.,
1991). Endothelial signaling that targets the host response to the injured area involves
localized co-expression of chemotactic factors and adhesion epitopes both on the endothelium
and on adhering blood cells. In a smoothly orchestrated manner, L-selectin guides the
unstimulated leukocytes to roll along the unstimulated endothelium. As an activated segment
of the endothelium (e.g., ELAM-1 and ICAM-1) is detected by the leukocyte, the rolling
slows down. This exposes the leukocyte to a local gradient of chemotactic factors long
enough for it to become activated.
Chemoattractant signals
The chemoattractant signals include activated complement proteins (C3a, C5a),
platelet activating factor (PAF), interleukin-8 (IL-8), and granulocyte-macrophage colony-
stimulating factor (GM-CSF). Once signaled, ligands for ICAM-1 are upregulated on the
leukocytes, such as Mac-1 (CD11b/CD18 integrin) and leukocyte function-associated antigen-
1 (LFA-1; CD11a/CD18 integrin), along with progressive shedding of the L-selectin, all of
which characterize the circumstances required for transendothelial migration (Hallenbeck and
Kochanek, 1998). Additional chemokines induced in the post-ischemic brain include
cytokine-induced neutrophil chemoattractant (CINC) with maximal mRNA expression
between 6 and 24 hours after permanent MCAO. Further, monocyte chemoattractant protein-1
(MCP-1) and macrophage inflammatory protein-1α (MIP-1α) show their peak mRNA
expression between 12 h to 2 days, with subsequent protein detection in the same
experimental model (Feuerstein et al., 1998, Kim et al., 1995). Taken together, the functions
of chemokines include activation of leukocyte integrins, guidance of leukocytes through the
endothelial junctions and underlying tissue to the site of inflammation, and finally activation
of effector functions of leukocytes within the tissue (Furie and Randolph, 1995).
Leukocytes
Leukocytes are considered to be key mediators of the host response in reperfusion
injury. The entry of leukocytes into the brain parenchyma is led by neutrophils
(polymorphonuclear leukocytes, PMNL) during the acute phase of infarction in the blood
vessels within and especially surrounding the lesion at 12 h and lasting up to 3 days (reviewed
by Kochanek and Hallenbeck, 1992, Clark et al., 1993). In the experimental setting of
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permanent MCA occlusion, leukocytes are suggested to enter via collateral blood flow the
area of infarction, but reperfusion makes their entry more rapid and manifold (Kochanek and
Hallenbeck, 1992). Cells of the macrophage and monocyte lineage are detected in the rat post-
ischemic tissue between 3 to 5 days after MCAO. The cells are initially dispersed around the
infarcted tissue and cluster in the necrotic tissue in weeks (Clark et al., 1993). The
mononuclear infiltrate may represent both monocyte-derived macrophages and endogenous
ameboid microglia (Kochanek and Hallenbeck, 1992). The postulated effects of leukocytes in
the pathogenesis of cerebral ischemia include: first, secondary microvascular failure by
plugging of microvessels (the so-called “no-reflow” phenomenon) or possibly through release
of vasoconstrictive mediators. Secondly is exacerbation of the blood-brain barrier and
parenchymal injury via release of proteolytic enzymes and by production of oxygen free
radicals, cytokines, or vasoactive lipid mediators. The destructive actions of toxic oxygen
species (including NO) and granule constituents released from neutrophils (elastase,
collagenase, and gelatinase) are speculated to be more efficient and more specific in an
environment created by the neutrophils through inactivation of proteinase inhibitors and
through simultaneous activation of latent proteinases than is achieved by oxidants alone
(Hallenbeck and Kochanek, 1998). Third, the initiation of thrombosis is a possible action of
monocytes due to expression of tissue factor leading to fibrin formation on cell surfaces
(Hallenbeck and Kochanek, 1998). The most convincing evidence for leukocyte involvement
in the pathophysiology of cerebral ischemia is derived from interventions applying
neutrophil-depletion and antiadhesion molecules, which have shown the best results in the
paradigm of MCAO with reperfusion. The beneficial effects observed include decreased
neutrophil infiltration into the brain tissue and reduced brain edema and infarct size, along
with improved neurological function (reviewed in Feuerstein et al., 1998, Hallenbeck and
Kochanek, 1998). Figure 6 summarizes the temporal occurrence of inflammatory changes
during cerebral ischemia and reperfusion.
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Figure 6. Temporal profile of recruitment of white blood cells and their subsequent functions in
ischemic brain tissue. Events (1-4) leading to white blood cell entry into brain parenchyma, guided by
mediators (at the bottom in bold) upregulated during cerebral ischemia. Time periods in parentheses
refer to peak mRNA expression of mediators and to detection of different white blood cell types in
brain parenchyma. Solid arrows mark activation by chemotactic factors. On the right, the consequences
of white blood cell activation are shown by dashed arrows marking factors released by leukocytes
(bold) and the resultant effects (non-bold). Abbreviations: ELAM-1 = endothelium-leukocyte adhesion
molecule-1, VCAM-1 = vascular endothelial adhesion molecule-1, ICAM-1 = intercellular adhesion
molecule-1, CD11/CD18 = leukocyte integrin, PAF = platelet activating factor, IL-8 = interleukin-8,
and GM-CSF = granulocyte-macrophage colony-stimulating factor, CINC = cytokine-induced
neutrophil chemoattractant, MCP-1 = monocyte chemoattractant protein-1, MIP-1α = macrophage
inflammatory protein-1α, PMNL = polymorphonuclear leukocytes, Mø/Macrophage =
monocyte/macrophage lineage cells, TF = tissue factor.
3.2. Do enhanced inflammatory reactions caused by stroke risk factors predispose to
stroke?
Stroke risk factors such as hypertension, diabetes, and advanced age carry a
predisposition to CNS insults in such a way that in rats with these risk factors an intracisternal
injection of endotoxin (a potent activator of inflammatory reactions) increases
thrombohemorrhagic lesions in the brain stem but not in rats without risk factors (reviewed in
Kochanek and Hallenbeck, 1992). Furthermore, rats with hypertension or of advanced age
show increased numbers of perivascular monocytes/macrophages around their
cerebrovascular arteries. Moreover, they release more TNF-α into serum and cerebrospinal
fluid (CSF) and additionally, into culture medium from carotid rings than do the control rats.
Their monocytes and cerebrovascular endothelial cells also are more responsive to TNF-α
and IL-1 in terms of leukocyte adhesion receptor expression and monocyte binding
(Hallenbeck and Kochanek, 1998). Finally, in old, spontaneously hypertensive rats, the
leukocyte (and neutrophil) counts were about 100% above the values in controls (Schmid-
Schönbein et al., 1991). This is in line with epidemiological findings of increased leukocyte
counts and recent acute infections as risk factors for stroke (Syrjänen et al, 1988, Ameriso et
al., 1991, Grau et al, 1995a and b). Chronic infectious diseases like chronic bronchitis,
periodontal disease (Grau et al, 1997), and chronic Chlamydia pneumoniae infections
(Wimmer et al., 1996) in fact, do carry an increased risk for stroke.
Mechanisms between infection and/or inflammation and thromboembolic
complications are, however, only partially understood and may include hyperviscosity,
thrombophilia (Reilly and Fitzgerald, 1993), and/or infection-associated disturbances in lipid
metabolism leading to advanced atherosclerosis (reviewed by Valtonen, 1991). Additionally,
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leukocytosis, increased levels of acute phase reactants such as C-reactive protein, and
formation of immune complexes may also lead to platelet aggregation (reviewed by Syrjänen
et al., 1988).
4. CYTOKINES AND CYCLOOXYGENASE-2 IN CEREBRAL ISCHEMIA
Cytokines can be characterized generally as hormone-like polypeptides that regulate
homeostasis, either via local action in a paracrine or in an autocrine manner or by entrance
into the circulation. Expression and activity of cytokines are increased under conditions of
tissue stress, which may include phases of rapid growth (for example, embryogenesis or tissue
repair), various perturbations of tissue homeostasis (for example, chronic inflammatory
disease or tumor growth), infection, and trauma. Cytokines exert an extremely broad range of
activity with extensive overlap between different cytokines, and a wide array of cells are able
to produce cytokines. Many cytokines and their receptors are expressed in the CNS and may
be expressed by invading immune, or by resident cells. Trauma in peripheral tissues may
induce cytokine-mediated events in the CNS, either via the circulation or through secondary
induction within the brain (Hopkins and Rothwell, 1995).
The cytokines are actually a family of mediators that can be grouped in several ways,
and many can be viewed as members of several groups. The classification can be based on
similarities in function, in structure, or in the receptor type that the cytokines bind to.
Classification according to the ability of unrelated cytokines to recognize their high-affinity
receptors that are members of a cytokine receptor family includes: 1) Class I or type I
cytokine receptors that bind hormones, interleukins, or colony-stimulating factors; also called
the hematopoietin receptor group. 2) Type II cytokine receptors that bind interferons and IL-
10 family cytokines, 3) Type III receptors are TNF or nerve growth factor (NGF) receptors. 4)
Type IV cytokine receptors or interleukin-1 receptors. 5) Receptor kinase family that exhibit
kinase activity of the intracellular portion of the receptor. 6) Chemokine receptors. Cytokine
members that belong to these cytokine receptor families are shown in table 2A. A functional
classification of cytokines is shown in Table 2B.
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Table 2A. Cytokine members of the cytokine receptor families
Cytokine receptor family Cytokine members
Class I cytokine receptors
(Hematopoietin receptors)
IL-2, -3, -4, -5, -6, -7, -9, -11, -12, -13, -15. GM-CSF,
G-CSF, LIF-1, CNTF, oncostatin M, cardiotrophin-1,
thrombopoietin, erythropoietin, GH, prolactin, leptin
Class II cytokine receptors
(Interferon receptors)
IFN-α, β, γ,and ω, IL-10 family
Class III cytokine receptors
(TNF/NGF receptors)
FasL, TNF-α, LT-β, CD27L, CD40L, NGF, TRAMP,
TRAIL
Class IV cytokine receptors IL-1α, IL-1β, IL-1ra, IL-18
Receptor kinase family EGF, TGF-α, IGF, heregulin, HGF, M-CSF, CSF,
PDGF, VEGF, FGF, NGF, BDNF, TGF-β
Chemokine receptors C- (“lymphotactin”), CC- (for example: MCP,
RANTES), CXC- (IL-8, PF-4, NAP-2), CX3C
(“fractalkine”)-chemokines
Table 2B. Functional classification of cytokine families
Family Members Major activities
Interleukins IL-1α, IL-,1β, IL-1ra, IL-2 to IL-23 Multiple tissue and immunoregulatory
activities; no similarity of activity
implied by membership in this family
Chemokines IL-8/NAP-1, NAP-2, MIP-1α and β,
MCAF/MCP-1, MGSA and RANTES
Leukocyte chemotaxis and cellular
activation
Tumor necrosis factor family TNF-α, TNF-β, CD 27 ligand, CD 30
ligand, CD 40 ligand, 4-1BB ligand,
OX 40 ligand, and FasL
TNF is similar to IL-1; in addition,
tumor toxicity, cytotoxicity, and
apoptosis
Interferons IFN-α, β, γ, and ω. Inhibition of intracellular viral
replication, and regulation of cell
growth; IFN-γ is primarily
immunoregulatory
Colony stimulating factors G-CSF, M-CSF, GM-CSF, IL-3, and
some other interleukins
Colony cell formation in bone marrow
and activation of mature leukocyte
functions
Growth factors EGF, FGF, PDGF, TGF-α, TGF-β,
and ECGF
Cell growth and differentiation
Neurotrophins BDNF, NGF, NT-3 – NT-6, and
GDNF
Growth and differentiation of neurons
Neuropoietins LIF, CNTF, Oncostatin M, and IL-6 Action on the nervous system, and
action via a related receptor complex
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Abbreviations: IL = interleukin. G, M, and GM-CSFs = granulocyte, macrophage, and
granulocyte/macrophage colony-stimulating factors. LIF-1 = leukemia inhibitory factor-1. CNTF =
ciliary neurotrophic factor. IFN = interferon. FasL = Fas ligand. TNF = tumor necrosis factor. NGF =
nerve growth factor. TRAMP = TNF receptor-related apoptosis-mediating protein. TRAIL = TNF-
related apoptosis inducing ligand. IL-1ra = interleukin-1 receptor antagonist. EGF = epidermal growth
factor. TGF-α, β = transforming growth factors α and β. IGF = insulin-like growth factor. HGF =
hepatocyte growth factor. PDGF = platelet-derived growth factor. VEGF = vascular endothelial cell
growth factor. FGF = fibroblast growth factor. BDNF = brain derived neurotrophic factor. MCP =
monocyte chemotactic protein. RANTES = regulated upon activation normal T-expressed and secreted
chemokine. PF-4 = platelet factor-4. NAP-1, 2 = neutrophil-activating peptides 1 and 2. MIP =
macrophage inflammatory protein. MCAF = monocyte chemotactic and activating factor. MGSA =
melanoma growth stimulatory activity. ECGF = endothelial cell growth factor. GDNF = glial-derived
neurotrophic factor. NT = neurotrophin. CD 30 = Hodgkin’s lymphoma antigen. CD 40 = B cell
antigen. CD 27, 4-1BB, OX 40 = T cell antigens. (Modified from Hopkins and Rothwell, 1995 and
Nagata and Golstein, 1995, Rothwell and Luheshi, 2000).
In sum, as pointed out by Rothwell and coworkers (1996), the evolutionary rationale
for cytokine production suggests that the synthesis and actions of cytokines in the brain must
be of biological advantage. Thus, many of the responses to systemic disease that are mediated
by cytokine actions on the brain, such as fever, hypothalamic-pituitary-adrenal (HPA) axis
activation, sleep, and behavioral changes, probably serve to limit infection or inflammation, to
conserve energy reserves, and to promote repair and recovery. In addition, neurotrophic and
protective effects of cytokines have been demonstrated in cerebral neurons. However, as with
many homeostatic functions, sustained or excessive activation of cytokine synthesis can prove
detrimental or even fatal. As an illustrative example, cytokine-mediated chronic suppression
of appetite and elevated body temperature lead to energy deficit and wasting (cachexia), and
prolonged somnolence and lethargy impair neuronal function.
In the following sections, two pro-inflammatory cytokines acting in synergy on the
brain are described in more detail. Interleukin-1 was among the first cytokines described and
was originally known as the “endogenous pyrogen” mediating fever. TNF-α was originally
identified as a systemic mediator of cachexia, tumor regression, and endotoxic shock with
partially centrally mediated symptoms (e.g., fever, HPA-axis activation, sleep and behavioral
changes). Ever since, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) have
attracted much of interest in regard to brain homeostasis and disease.
Cyclooxygenase (COX) is the rate-limiting enzyme in the conversion of prostanoids
from cell membrane lipids. The prostanoids may play a role in memory function, besides their
participation in pathological brain processes through vasoconstrictive, prothrombotic,
inflammatory, or direct neurotoxic action. Knowledge of cerebral COX-2 expression has
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expanded after its cloning and characterization (O’Banion et al., 1992) and its activity in the
CNS explains the rapid appearance of cerebral prostanoids as described decades before.
4.1. Interleukin-1β (IL-1β)
Two biologically distinct but structurally related interleukin-1 molecules have
been cloned, IL-1β and IL-1α. These two share 26% homology in their amino acid sequence
in humans. They are coded by different genes, both located on chromosome 2. The mRNA
coding for IL-1β predominates over the coding for IL-1α (Dinarello, 1988). Both IL-1 forms
are initially translated as precursor polypeptides of 31 kDa, and the generation of the mature
peptide of the size 17.5 kDa results from cleavage by serine protease(s) later named
interleukin converting enzyme (ICE) (Friedlander et al., 1997, Schielke et al., 1998). Two IL-
1 receptors have been identified on peripheral cells: an 80-kDa type I receptor, which binds
IL-1α and IL-1β with similar affinity, and a 68-kDa type II receptor, which shows greater
affinity for IL-1β (Rothwell et al., 1996). It has been suggested that the type II receptor is not
coupled to signal transduction mechanisms and may act as a decoy neutralizing IL-1 action
(Sims et al., 1993). Both receptors exist in membrane-bound and soluble forms (Watkins et
al., 1999). Findings regarding the existence of these receptors in the brain are somewhat
controversial (Rothwell, 1991). Both have been identified in rodent brain by in situ
hybridization and polymerase chain reaction (PCR) analysis (Parnet et al., 1994), but
radioligand binding (using IL-1α) has revealed only sites characteristic of the type I receptor
and has failed to show binding in the hypothalamus (Haour et al., 1990, Ban et al., 1991), the
major site of IL-1 action on the brain (reviewed in Rothwell et al., 1996). Furthermore, a
naturally occurring competitive antagonist of IL-1 has been characterized, the interleukin-1
receptor antagonist (IL-1ra). This molecule shares sequence homology with IL-1α and IL-1β
and appears to have little or no agonist activity (Dinarello and Thompson, 1991). Yet other
modifiers of the interleukin-1 system are IL-1 receptor accessory protein (IL-1RacP).
Association of accessory protein with IL-1R is required for signaling through IL-1 type I
receptor (Watkins et al., 1999). IL-1ra fails to trigger this association and does not lead to
subsequent intracellular signaling (Rothwell and Luheshi, 2000). A further suggested
endogenous inhibitor of IL-1 action is lipocortin-1 (for review see Rothwell et al., 1996).
Also, a putative new member of the IL-1 family has been identified, namely IL-18, that is also
activated by ICE cleavage and shares several features with the IL-1family though its actions
are not identical to IL-1 (Touzani et al., 1999).
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IL-1β in normal brain homeostasis
Normal brain exhibits IL-1β constitutively in specific areas of rodent and human
brains(Breder et al., 1988, Higgins and Olschowka, 1991, Lechan et al., 1990). IL-1β may act
as a mediator or modulator of normal neuronal growth (Guilian and Tapscott, 1988, Rothwell,
1991). Recently, it has been shown to be a physiological mediator maintaining the long-term
potentiation (LTP) responsible for learning and memory (Schneider et al., 1998). On the other
hand, also inhibition of LTP maintenance has been reported by IL-1β (reviewed in Rothwell
and Luheshi, 2000). Interestingly, low concentrations of IL-1 exert a neurotrophic effect and
neuroprotective action against excitotoxins (Strijbos and Rothwell, 1995, Mattson, 1990).
Central IL-1 action is summarized in Table 3.
As a systemic response, increased circulating levels of IL-1 have been associated with
vigorous exercise, and with ovulation and parturition, in the absence of apparent infection or
injury (reviewed by Dinarello, 1991).
Table 3. Centrally mediated IL-1 action.
Local effects in
brain
Endocrine action Metabolic
Action
Behavioral action Immune action
Altered EEG and
neuronal activity
Hypothalamic-
pituitary hormone
release
Fever Sleepiness Peripheral IL-6
release induction
Modulation of long-
term potentiation
Pituitary-adrenal
activation
Increased metabolic
rate
“sickness behavior” Decreased
peripheral IL-2
production
Cortical inhibitory
postsynaptic
function
Insulin release Sympathetic
activation of brown
fat
Reduced natural
killer cell activity
Neurotransmitter
release/turnover
Hypophagia Leukocytosis
Induction of NGF Altered gastric
function
Hepatic acute phase
protein synthesis
Self-induction (IL-
1β)
Astrogliosis
Neovascularization
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Abbreviations: EEG = electroencephalogram, NGF = nerve growth factor (Modified from Rothwell,
1991 and Rohtwell and Luheshi, 2000).
IL-1β in brain pathophysiology
A general pathophysiologic role for IL-1β in the brain is supported by the detection of
IL-1β and its receptor mRNAs and protein in injured brain tissue, and by increased IL-1
concentrations in the CSF in response to injury or inflammation. In human neurodegenerative
disease, increased expression of IL-1β appears in Alzheimer’s type of dementia, and Down’s
syndrome (Griffin et al., 1989), consistent with the hypothesis linking brain injury or
inflammation with the subsequent development of Alzheimer’s disease (Allsop et al., 1990).
Additional observations of increased IL-1 expression in chronic cerebral degenerative
conditions in humans include multiple sclerosis, temporal lobe epilepsy, Parkinson’s disease,
and motor neuron disease (Rothwell et al., 1997).
IL-1β in pathophysiology of acute cerebral ischemia
Specific participation of IL-1β in the pathophysiology of acute cerebral ischemia is
supported by several lines of evidence. First, several studies have reported induced IL-1β
gene expression in brain ischemia (Minami et al., 1992, Liu et al., 1993, Buttini et al., 1994,
Yabuuchi et al., 1994, Wang et al., 1994, Szaflarski et al., 1995, Zhai et al., 1997). IL-1β
mRNA is already detected half an hour after an ischemic insult, the peak of mRNA
expression occurs between (3-) 6 to 12 h, and declines by 2 to several days (Minami et al.,
1992, Liu et al., 1993, Yabuuchi et al., 1994, Buttini et al., 1994, Wang et al., 1994, Szaflarski
et al., 1995). The brain cells capable of IL-1β synthesis include neurons, glial cells (microglia
and astrocytes), and endothelial cells, besides invading inflammatory cells (Feuerstein et al.,
1998). To date, the detection of IL-1β protein after ischemic insult is restricted to elevated IL-
1β levels after MCAO (Iannotti et al., 1993, Hillhouse et al., 1998, Legos et al., 2000) and
after a transient global ischemic insult (Saito et al., 1996) detected by immunoassay.
Immunohistochemistry has been applied only in very recent studies with permanent MCAO
(Zhang et al., 1998, Davies et al., 1999, Orzylowska et al., 1999). Furthermore, only one
study describes changes in IL-1 receptors and in IL-1ra gene expression after focal ischemia
(Wang et al., 1997). The latter study also addresses additional modulators of IL-1β actions,
namely interleukin-1α and interleukin-1 accessory protein.
It has been well documented that administration of recombinant IL-1β into the rat
brain produces marked exacerbation of ischemic brain damage (Yamasaki et al., 1995,
Loddick and Rothwell, 1996). The striatum has been suggested to be the specific site of IL-1β
action (Stroemer and Rothwell, 1998). Accordingly, IL-1 antagonism has been shown to be
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neuroprotective in vivo, since either intracerebroventricular (Relton and Rothwell, 1992,
Loddick and Rothwell, 1996) or peripheral (Garcia et al., 1995, Relton et al., 1996) injection
of recombinant human IL-1 ra or administration of IL-1β neutralizing antibody (Yamasaki et
al., 1995) in rats markedly diminished the size of the infarct, edema, and the neurologic
deficits after MCAO. In accordance, mutant mice deficient in interleukin-1 converting
enzyme (ICE) show amelioration of ischemia-induced brain injury (Friedlander et al., 1997,
Schielke et al., 1998), and mice overexpressing ICE inhibitory protein develop smaller
infarcts and show fewer neurological deficits and reduced edema, besides lower IL-1β levels
(Hara et al., 1997). Rothwell and coworkers (1997) have proposed that in experimental
interventive studies it has been shown that IL-1ra administration reduces brain damage caused
by focal, permanent, or reversible ischemia, similar to findings from excitotoxic, traumatic, or
inflammatory brain damage. IL-1ra also inhibits the detrimental effects of heat stroke and
epilepsy. The finding that IL-1 inhibition results in neuronal protection in such a variety of
different insults suggests its participation in a step of the pathophysiologic pathway toward
neuronal death that is common to all insults (Rothwell et al., 1997). As a further effect,
repeated administration IL-1β prior to cerebral ischemia has the capacity of eliciting ischemic
tolerance (Ohtsuki et al., 1996a).
Mechanisms of IL-1β action in ischemic brain
The mechanisms of IL-1β action in the post-ischemic brain have remained obscure,
since IL-1β itself is not neurotoxic in the absence of other stimuli, and in vitro experiments
have failed to mimic IL-1 effects observed in vivo. This underscores the importance of
discovering the changes in IL-1β expression at cellular level in the whole brain concomitantly
with changes in receptor expression determining the target cells of IL-1β action. Furthermore,
IL-1β may interact with other molecules released or induced by damage, or it may affect only
compromised neurons (Rothwell et al., 1997).
Excessive local levels of IL-1β may result in transformation of the endothelium
towards a prothrombotic state (Hallenbeck and Kochanek, 1998); activation of microglia and
astrocytes leads to further release of cytokines and possible scarring due to astrogliosis
(Guilian and Tapscott, 1988). Various mediators have been identified that are induced or
activated by IL-1β and may subsequently contribute to neuronal damage. These include
phospholipase A2, cyclooxygenase, and their products, nitric oxide, superoxides, complement,
adhesion molecules, beta-amyloid precursor protein (betaAPP), and corticotrophin-releasing
factor among numerous other known and probably many unidentified ones (Rothwell et al.,
1997).
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As a result of peripheral IL-1ra administration, fewer leukocytes enter the ischemic
hemisphere (Garcia et al., 1995), suggesting an important role for IL-1β in their recruitment, a
finding later repeated in mutant mice overexpressing IL-1ra (Yang et al., 1998a). Participation
of IL-1β in the induction of ICAM-1 during cerebral ischemia has been indirectly shown in
interleukin-1β converting enzyme (ICE) knock-out mutants that exhibited reduced ICAM-1
expression (Yang et al., 1999). Furthermore, in ICAM-1-deficient mice, ischemic lesion size
was reduced and ICAM-1 seemed to play a role in microcirculatory failure and subsequent
development of infarction after focal ischemia (Kitagawa et al., 1998), consistent with a
hypothesis of the crucial role of leukocytes in expansion of ischemic damage. Another
possible pathophysiologic role for IL-1β stems from ICE as a caspase recruited in the
cleavage of mature IL-1β from the pro-IL-1β polypeptide, and on the other hand, a caspase
mediating apoptotic cell death. Although the significance of apoptosis in ischemic cell death
remains to be elucidated, recent findings on reduced brain injury as a result of MCAO in ICE-
deficient mice (Schielke et al., 1998), as well smaller infarction size and milder neurological
deficits in transgenic mice overexpressing ICE inhibitory protein (Hara et al., 1997) support
the beneficial effect of apoptosis-inhibition in ischemic damage. In addition, injection of IL-
1β into normal rat brain leads to increased DNA fragmentation as shown by TUNEL-staining,
in addition to enhanced inflammatory response and vasogenic edema (Holmin and Mathiesen,
2000).
The intracellular signaling following IL-1R1 by IL-1β may involve the activation of
transcription factors like NF-κB and activation of protein kinase pathways including stress-
activated kinases like mitogen-activated protein kinase (MAPK) p38 (p38 MAPK), p42/p44
MAPK, and c-jun N-terminal kinase-1 (JNK-1) (Rothwell and Luheshi, 2000). Very recently,
inhibition of p38 MAPK was shown to be neuroprotective in experimental focal ischemia
(reviewed in Barone and Feuerstein, 1999).
4.2. Tumor necrosis factor-α (TNF-α)
Remission of sarcoma after repeated erysipelas infections, as described by Dr.
William B. Coley in 1893 may be the first description of a TNF-α effect induced by a
streptococcal infection and leading to reversed tumor growth (Coley, 1893). In 1962, an
endotoxin injection was reported to result in hemorrhagic tumor necrosis in mice (O’Malley
et al., 1962), and in 1975 this effect was understood to be due to a circulating protein called
tumor necrosis factor (Carswell et al., 1975). Almost one hundred years after its initial
description, TNF was purified (Pennica et al., 1984). Later it was found to be identical with a
protein called cachectin (Beutler et al., 1985). On the other hand, another cytokine called
lymphotoxin (LT) was described in 1968 and was later found to have 35% homology with
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TNF (Li et al., 1987). The genes encoding for these both were located on human chromosome
6, they bound to the same receptor, and they shared many activities. These observations
prompted the nomenclature of LT to change to TNF-β and TNF to become TNF-α
(Bemelmans et al., 1996).
Monocytes/macrophages are the main producers of TNF-α, but other cells such as T-
lymphocytes, NK-cells, Kuppfer cells, smooth muscle cells, endothelial cells, and neural cells
including microglia, astrocytes, and neurons can also produce TNF-α (Bemelmans et al.,
1996, Barger, 1998). Several lines of evidence suggest a specific TNF-α –converting enzyme
(TACE), a member of the matrix metalloproteinase family, to be at least partially responsible
for the activation of TNF (reviewed in Ksontini et al., 1998). A mature form of TNF-α of the
size 17 kDa is released, besides a membrane-associated form of 26 kDa. The secreted TNF-α
is suggested to be derived from the membrane-associated form also through matrix
metalloproteinase activity. In the circulation, TNF-α is mostly detected in a trimeric form
(Ksontini et al., 1998).
Two distinct surface TNF receptors exist on a majority of cells: Type I TNFR
(TNFR1), a receptor of 55 kDa molecular weight (TNFR p55), and Type II TNFR (TNFR2), a
75 kDa receptor (TNFR p75). The TNF receptors belong to a family of proteins called the
TNF and nerve growth factor (NGF) receptor family that show sequence homology in their
extracellular structure. In addition to TNF and NGF receptors, these include Fas, B cell
antigen CD40, T cell antigens OX40, 4-1 BB, and CD27, Hodgkin’s lymphoma antigen
CD30, and the soluble protein of Shope fibroma virus (SFV-T2). The only intracellular region
with relative similarity is evident in Fas and TNFR-1, a region called the death domain, which
is necessary and sufficient for apoptotic cell death transduction (Nagata and Golstein, 1995).
No homology exists between the intracellular parts of the two TNF receptors, suggesting
different signaling pathways inside the cells (reviewed in Bemelmans et al., 1996). The roles
of the two TNF receptors in response to TNF-α binding remain to be fully elucidated, but
generally the p55 receptor is suggested to mediate signal transduction leading to most TNF
effects, with the p75 receptor serving as a catcher and deliverer that “passes on” bound TNF
to the p55 receptor (reviewed in Bemelmans et al., 1996 and Ksontini et al., 1998). Yet, acting
as another regulator of TNF-α effects, soluble TNF receptors (sTNFR) consisting of
extracellular parts of TNF receptors have been identified in the systemic circulation. Their
proposed roles include a capacity to buffer excess TNF by binding it. Receptor shedding from
the cell surface may make cells temporarily less sensitive to the harmful effects of TNF-α.
This may lead to prolonged TNF effect by slow release over time (Bemelmans et al., 1996).
Besides the participation of TNF-α in acute infectious and inflammatory diseases
including trauma, sepsis and septic shock, a mediator role also in chronic diseases such as
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rheumatoid arthritis, Crohn’s disease, and ulcerative colitis has been suggested in humans
(Ksontini et al., 1998). In those first two autoimmune diseases, at least temporary relief of
symptoms has been achieved in randomized, double-blind clinical trials with antibodies
against TNF-α (Elliot et al., 1994, Stack et al., 1997). On the other hand, in preliminary
clinical trials with isolated perfusion of the affected organ with exogenous TNF-α for patients
with solid tumors of muscle tissue, liver, or kidney, or with malignant pleural effusions or
lung metastases, promising remissions have been reported (Eggermont et al., 1997, Rauthe et
al., 1997). The antineoplastic potential of TNF-α has been suggested to be due to disrupted
neovascularization of solid cancers or secondary to apoptosis induction in selected tumor cell
populations (reviewed in Ksontini et al., 1998).
TNF-α in normal homeostasis
A role for TNF-α in normal homeostasis has been suggested by the wide expression
of TNF and receptors throughout embryonic development in many tissues. However, tumor
necrosis factor-α deficient mice have developed normally and shown no structural or
morphological abnormalities (Marino et al., 1997), likewise mice transgenic for TNF have
revealed no obvious developmental role for TNF (Kolls et al., 1994). Accordingly, knock-out
mice lacking TNFR1 showed only subtle effects on hematopoietic progenitor cell numbers
(Zhang et al., 1995). Furthermore, double knock-out mice devoid of both TNF receptors show
no abnormalities in development or basic neurological behavior (Bruce et al., 1996). The most
obvious beneficial role for TNF in TNFR1 knock-out mice has been suggested to be defense
against infection, because certain infections were uncontrolled in these mice (Rothe et al.,
1993, Marino et al., 1997). Taken together, the most important functions of TNF are
suggested to take place in the mature immune system, in which one of the major roles of
TNF-α is coordination of the acute phase reactions, including induction of other cytokines, C-
reactive protein, and serum amyloid A through liver stimulation (reviewed by Barger, 1998).
TNF-α is the major cytokine mediator of the systemic manifestations of sepsis and
septic shock (Grau and Maennel, 1997). As a local effect, TNF-α causes changes in the
endothelium of capillaries, which are made attractive to circulating leukocytes. This is caused
by induction of adhesion molecules and by direct and indirect chemotactic signaling of TNF-
α. Finally, systemic TNF-α activity is suggested to participate in editing (for example through
apoptosis) of injured cells or immune cells and in repair of inflammatory damage (Marino et
al., 1997). TNF-α activity, upon excessive induction, may also result in either necrotic or
apoptotic cell death (Laster et al., 1988, Barger, 1998).
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TNF-α in cerebral pathophysiology
Elevated levels of TNF-α in brain tissue, cerebrospinal fluid (CSF), and plasma have
been observed in several human CNS disorders, including infectious and immunological
diseases like bacterial meningitis (Leist et al., 1988), cerebral malaria (Grau et al., 1989), and
AIDS (Tyor et al., 1992, Sippy et al., 1995) as well as in experimental, non-infectious acute
brain insults such as ischemic stroke (Feuerstein et al., 1994) and traumatic brain lesions
(reviewed in Barger, 1998). Similarly, participation of TNF-α in human CNS diseases such as
multiple sclerosis (MS) (Hofman et al., 1989, Probert et al., 1995), Parkinson’s disease (Mogi
et al., 1994), and Alzheimer’s disease (reviewed in Mattson et al., 1997) is supported by the
detection of TNF-α in diseased brain parenchyma or CSF and in plasma. Apoptosis is under
genetic control and can be triggered by many factors, including cytokines like TNF-α (Majno
et Joris, 1995). The list of CNS disorders with evidence for increased apoptosis overlaps with
TNF-α associated diseases and includes neurodegenerative disorders like Alzheimer’s
disease, Parkinson’s disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar
degenerations, and ischemic injury (reviewed in Thompson, 1995, Schulz et al., 1999).
Disappointingly, in contradiction to experimental data, in a randomized, placebo-controlled
clinical trial for MS, a recombinant soluble TNF receptor p55 immunoglobulin fusion protein
blocking the TNF-effect, increased relapse rate, early relapses, and possibly longer and more
severe relapses were encountered, besides a number of adverse effects from this medication
(Arnason et al, 1999, commented by Schwid and Noseworthy, 1999).
TNF-α in pathophysiology of acute cerebral ischemia
Several investigations with experimental stroke models have demonstrated that TNF-
α is activated in the ischemic brain both the at mRNA (Wang et al., 1994, Szaflarski et al.,
1995, Zhai et al., 1997) and the protein level (Liu et al., 1994, Saito et al., 1996, Buttini et al.,
1996, Botchkina et al., 1997, Uno et al., 1997, Bertorelli et al., 1998, Gregersen et al., 2000).
TNF-α is one of the earliest cytokines induced, as its mRNA is already detectable only 1 hour
after an ischemic insult and peaks between 4 and 12 hours. To date, the experimental
paradigm has been permanent middle cerebral artery occlusion (PMCAO) in most of these
studies with the exception of the one describing mRNA changes after transient MCAO (Wang
et al., 1994). In recent publications, the cellular origin of TNF-α mRNA expression has been
suggested to be mainly microglial cells (Buttini et al., 1996, Gregersen et al., 2000). Two
studies on transient global ischemia have described protein levels investigated either by a
bioassay (Saito et al., 1996) or by immunohistochemistry (Uno et al., 1997). Only one study
describes TNF receptor changes due to ischemia (Botchkina et al., 1997). Furthermore, only
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preliminary histological description are available of TNF-α protein expression in sporadic
cases of human cerebral infarction during the acute phase (Tomimoto et al.,1996).
Mechanisms of TNF-α action in brain ischemia
The net effect of TNF-α on the brain remains an open question. TNF-α has been
reported to have both neurotoxic and neuroprotective effects either in cell culture experiments
or in animal models of cerebral ischemia. It is evident that in the cell culture environment, the
composition of neural cell types is crucial in estimation of TNF-α effects on neurons, and it
has been speculated that the detrimental effects may be mediated by TNF-activated microglial
(Chao et al., 1993) or astroglial cells (Akassoglou et al., 1997), and the direct TNF-α effect on
neurons is neuroprotective (Barger, 1998, Loddick and Rothwell, 1999). TNF-α injection into
normal adult rodent brain has led to no parenchymal damage or behavioral changes despite
temporary leukocyte invasion (Wright and Merchant, 1992, Yamasaki et al., 1992). In
contradiction to this, in rats undergoing focal cerebral ischemia (Barone et al., 1997) TNF-α
injection resulted in loss of neurons. Part of this discrepancy may be explained by differences
between a mouse and a rat or may be due to differential activation of TNF receptor subtypes
by recombinant TNFs originating from another species. Specifically, human TNF-α used in
the first two studies does not activate the rodent TNFR2 efficiently (Lewis et al., 1991). The
difference in TNF effects may also depend on the status of the organism, as discussed above
(healthy vs. injured; Feuerstein et al., 1994, Loddick and Rothwell, 1999).
Administration of TNF binding protein attenuates infarct volume in mice (Nawashiro
et al., 1997a) and rats after PMCAO (Dawson et al., 1996, Barone et al., 1997) as well as after
transient MCAO both in mice (Yang et al., 1998b) and in rats (Lavine et al., 1998).
Interestingly, in mice, prior treatment with small amounts of TNF-α induced ischemic
tolerance when given 48 hours before PMCAO (Nawashiro et al., 1997b) but in rats a similar
amount of TNF-α administered only 24 h before either transient or permanent MCAO
exacerbated ischemic injury (Barone et al., 1997).
Several proinflammatory and neurotoxic effects have been reported for TNF-α in the
CNS, which might account for its pathophysiologic activity. These include: upregulation of
endothelial and leukocyte adhesion molecule expression, enhancement of inflammatory cell
infiltration and activation, induction of the synthesis of other inflammatory cytokines
including IL-1β, synergy with IL-1β, procoagulant endothelial action, disruption of the blood-
brain barrier, demyelination of neurons, and gliosis (Pober and Cotran, 1990, Megyeri et al.,
1992, Sharief and Thompson, 1992, Feuerstein et al., 1994, Hallenbeck, 1994, Probert et al.,
1995, Gregersen et al., 2000), and also induction of apoptotic cell death (reviewed in
Bredesen, 1995). In experimental stroke models, TNF-α seems to exacerbate ischemic
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neuroinjury through aggravation of the inflammatory response (Dawson et al., 1996, Barone
et al., 1997, Nawashiro et al., 1997a, Meistrell III et al., 1997, Lavine et al., 1998) or through
inhibition of a survival peptide (Venters et al., 1999).
In addition to its suggested role in acute ischemic brain damage, TNF-α may also
play a role in the more chronic immunomodulatory response associated with stroke risk-
factors such as age, hypertension, and diabetes mellitus (Hallenbeck, 1994, Sirén et al., 1992,
Sirén et al., 1993, reviewed by Kim, 1996). On the other hand, TNF-α signaling possesses
another facet, namely neuroprotection, possibly due to (astro)glial cell proliferation or
promotion of growth-factor release in settings of neuroinjury in vitro as well as in ischemic
brain damage in vivo (Mattson et al., 1995, Mattson et al., 1997, Cheng et al., 1994, Barger et
al., 1995, Bruce et al., 1996, Shen and Shiosaki, 1997, Gary et al., 1998). Further mechanisms
of neuroprotection by TNF-α are discussed in the next chapter on intracellular signaling. A
summary of interventions on TNF-α signaling in the ischemic brain is presented in Figure 7.
NEUROPROTECTION                  NEUROTOXICITY
Figure 7. Interventions on TNF-α from in vitro and in vivo experiments with ischemic insults. The
role of TNF-α in ischemic injury is controversial, with results affected for example by differences in
the model system (cell culture composition; cell culture vs. in vivo experiment), species differences,
intensity of insult, administration of drug therapy (pretreatment vs. treatment during or after ischemia),
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and the state of the specimen prior to insult (normal vs. injured brain; modifications by life-long risk
factors). Abbreviations: p55/p75-/-KO-mice = knock-out mice lacking p55 and p75 TNF receptors;
p55-/- KO-mice = homozygotes lacking p55 TNF receptor. p75 ASO + rHTNF-α = antisense
oligonucleotide against p75 TNFR given prior to TNF-α administration. p75 ASO + hypoxia =
oligonucleotide treatment preceding hypoxia. rHTNF-α, rmTNF-α, rMuTNF-α = recombinant human
TNF-α, and mouse, murine equivalents. References in parentheses are the original publications.
Intracellular TNF-α signaling
The intracellular signaling of TNF-α has inspired a vast body of investigation. TNF
actions are initiated by the binding of TNF-α to its type I receptor (TNFR1) and type II
receptor, TNFR2. Both receptors are expressed on glial and nerve cells as well as on
infiltrating leukocytes (see Gregersen et al., 2000). Furthermore, they are overexpressed in
neurons and in vascular cells of the ischemic cortex after PMCAO (Botchkina et al., 1997).
TNFR1 contains cytoplasmic domains that may either induce apoptosis or (alternatively)
induce activation of nuclear factor-kappa B (NF-κB), a transcription factor controlling several
downstream genes important in immune system function. The apoptotic and inflammatory
effects are suggested to diverge at the level of the TNF-receptor 1-associated death domain
protein, TRADD (Hsu et al., 1995, Barger, 1998, Ksontini et al., 1998, Gregersen et al., 2000)
(Figure 8). NF-κB activation has been suggested to modulate voltage-dependent calcium
channels and glutamate receptors (Furukawa and Mattson, 1998), which may explain the
stabilizing effect of TNF-α in neuronal calcium metabolism (Cheng et al., 1994). In addition,
neuronal antioxidant enzyme induction by TNF-α may be mediated through NF-κB
activation, as suggested by Mattson and coworkers (1997). Additionally, binding of TNF-α to
TNFR2 may transduce growth and cellular activation signals, besides activating intracellular
cascades leading to cell death (Barger, 1998, Ksontini et al., 1998, Gregersen et al., 2000).
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Caspase-8
Cell death
TRAF2
TRAF1
NF-κB
Antioxidants ?
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-
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Figure 8. Hypothetical connections of TNF signal transduction. Intracellular proteins interacting
with cytosolic domains of two TNF receptors have been identified as TNF-receptor 1-associated death
domain protein (TRADD), that preferentially interacts with the death domain (DD) of TNFR1.
TRADD can also bind (Fas-associated death domain protein) FADD and TNF receptor-associated
factor 2 (TRAF2) and transduce the signal through them. A possible downstream factor leading to
cellular death is caspase 8, a cysteine protease that may be a relative of ICE. TRAF2 in turn appears
responsible for stimulation of NF-κB by TNFR1. TRAF2 also interacts directly with TNFR2 and when
complexed with TRAF1, can recruit an inhibitor of apoptosis protein (IAP) besides NF-κB activation.
Suggested mechanisms of cellular death prevention through NF-κB activation include antioxidants,
stabilized Ca2+ metabolism, and gene induction of protective proteins (Modified from Wallach, 1997,
Barger, 1998).
4.3. Cyclooxygenase-2 (COX-2)
The rate-limiting enzyme in the production of prostanoids from arachidonic acid
(AA) is cyclooxygenase (COX; prostaglandin G/H2 synthase, PGHS). The prostanoids
(prostaglandins, prostacyclins, and thromboxanes) are released when AA is liberated from the
breakdown of cell membrane phospholipids due to phospholipase A2 (PLA2) activity in
response to cellular stress. Two isoforms of cyclooxygenase enzyme have been characterized
(Herschman, 1994): COX-1 is the constitutively expressed form that leads to the production
of prostanoids responsible for gastric cytoprotection, normal renal maintenance, and vascular
functions under normal homeostasis. The inducible form, COX-2, has been suggested to play
a role both in normal physiological processes mediated by prostanoids, including mitogenesis,
cellular differentiation, and in pathophysiology including inflammation (Herschman, 1994,
Dinchuk et al., 1995, Pasinetti, 1998). Substantial experimental and clinical evidence
demonstrates the importance of prostaglandins in immune and inflammatory functions,
wound healing, female reproductive biology involving luteinization, ovulation, and
parturition, bone development, glomerular filtration and water balance, and in hemostasis. In
turn, prostaglandin aberrations have been associated with disease states such as arthritis,
asthma, bone resorption, cardiovascular disease, nephrotoxicity, atherosclerosis, hypotension
and shock, acute inflammation, immunosuppression, gastric ulcers, and cancer has been
shown. Moreover, inhibition of prostaglandin production by use of the use of non-steroidal
anti-inflammatory drugs (NSAID) not only reduces pain, fever, and inflammation, but also
reduces the risk for cardiovascular diseases, and reduces the incidence of colon cancer, as
evidenced by epidemiological studies (Herschman, 1994).
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COX-2 in normal brain homeostasis
Distinct from peripheral tissues, in the brain, the main isoform of cyclooxygenase is
COX-2, which is expressed in the normal rodent brain (Yamagata et al., 1993) and also in
small amounts in the human brain (O’Neill and Ford-Hutchinson, 1993). Yamagata and
coworkers (1993) demonstrated COX-2 to be induced in neurons of discrete brain areas in
response to NMDA receptor-dependent physiological synaptic activation. Thorough
localization studies have suggested that the COX-2 detected in dendrites and neuronal bodies
is involved in processing and integration of visceral and sensory input and in elaboration of
autonomic, endocrine, and behavioral responses (Breder et al., 1995). The developmental
profile of COX-2 expression coincides with the critical period for activity-dependent synaptic
remodeling of the maturing postnatal CNS (Kaufmann et al., 1996). This capacity of neurons
to long-term changes in response to neural activity is a prerequisite for learning and memory,
as well as for adaptive responses to pathological stimuli (Yamagata et al., 1993). Another
constitutive function for COX-2 is to couple synaptic activity in the somatosensory cortex an
accompanying increase in blood flow to that area (Niwa et al., 2000). Figure 9 summarizes
COX-2 induction and associated activities.
Figure 9. Factors inducing COX-2 and resultant actions in health and disease. Thin arrows
indicate inducers of COX-2 and bold arrows the major actions resulting from COX-2 enzymatic
activity in the periphery and CNS. The primary prostanoids mediating COX-2 action locally at the
periphery are at the bottom. Abbreviations: PGE2 and PGF2α = prostaglandins E2 and F2α. PGI2/TxA2
= prostacyclin I2 and thromboxane A2.
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COX-2 in brain disease
Production of vasoactive prostanoids is a well-known biochemical sequelae of
cerebral ischemia (Moskowitz et al., 1984, Kempski et al., 1987, Stevens and Yaksh, 1988),
edema, and other types of CNS disorders (Gaudet et al., 1980, Maier-Hauff et al., 1984,
Baethmann et al., 1989, for review see Farooqui and Horrocks, 1991). The major
prostaglandins produced also in human brain include PGD2, PGE2, and PGF2α (Ogorochi et
al., 1984). The prostanoids may exacerbate tissue injury through vasoconstrictive,
prothrombotic, chemoattractant, or direct neurotoxic action (see Chen et al., 1995). A vast
body of literature has accumulated on prostanoids in brain pathology over decades, but only
during the last few years has interest shifted to cerebral COX-2 expression with biochemical
tools available for its detection.
As indirect evidence for participation of COX-2 also in human brain pathology,
epidemiological studies have suggested a delayed onset and slower progression of
Alzheimer’s disease (AD) in patients being treated with NSAIDs for rheumatoid arthritis
(McGeer et al., 1996, Pasinetti, 1998). Moreover, in a small pilot study, indomethacin
appeared to slow the advance of AD (Rogers et al., 1993) and larger clinical prospective
studies are under way (Pasinetti, 1998). Other human CNS disease in which cyclooxygenase
activation may play a role include spinal cord injury, epilepsy (Farooqui and Horrocks, 1991),
and HIV-associated dementia (Griffin et al., 1994).
COX-2 in brain ischemia
An explosion of descriptions of COX-2 in the brain has occurred in the literature
during the last few years. In ischemia, COX-2 expression has been described after transient
MCAO (Planas et al., 1995, Miettinen et al., 1997, Nogawa et al., 1997, Kinouchi et al., 1999,
Planas et al., 1999) or permanent MCAO (Collaço-Moraes et al., 1996, Kinouchi et al., 1999),
and after global ischemia (Ohtsuki et al., 1996b, Koistinaho et al., 1999, Matsuoka et al.,
1999). The most recent publications show cerebral immunolocalization of COX-2 in human
brain after resuscitation due to cardiac arrest (Maslinska et al., 1999), and in chronic ischemia
due to other brain pathologies (Tomimoto et al., 2000), and after acute ischemia due to MCA
occlusion (Iadecola et al., 1999). Moreover, increased cerebral COX-2 immunoreactivity is
associated with enhanced enzymatic function, as evidenced by increased prostaglandin
production in the CNS (Nogawa et al., 1997).
Long before the descriptive studies on COX-2 in brain ischemia, attenuation of post-
ischemic brain hypoperfusion had been shown in a mammalian model of brain ischemia to
result from unselective cyclooxygenase inhibition (Hallenbeck and Furlow, 1979). More
recent studies in rodents have confirmed the same effect. Moreover, unselective
cyclooxygenase inhibition reduced blood-brain barrier permeability and infarct volume (Chen
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et al., 1995), even administered after ischemia (Yrjänheikki et al., 1999). Cole et al. (1993)
demonstrated that reduction in infarct volume was evident only when reperfusion was
allowed. In global ischemia, unselective cyclooxygenase inhibitor pretreatment ameliorated
delayed neuronal death (Nakagomi et al., 1989, Clemens et al., 1991), reduced free radical
production in vulnerable neuronal areas (Hall et al., 1993), and reduced the number of
TUNEL-stained neurons as a sign of protection from delayed DNA fragmentation (Kondo et
al., 1998). With the selective COX-2 antagonists later available, reduced infarct volume and
attenuation in the elevation of prostaglandin E2 has been shown in a transient focal ischemia
model with repeated drug administration (Nogawa et al., 1997). Lower prostaglandin
production was also evident in global ischemia in addition to prevention of delayed neuronal
death (Nakayama et al., 1998).
Mechanisms of COX-2 action in the brain
While COX-2 is the main cerebral cyclooxygenase isoform, it may play a role
divergent from its mostly inflammatory action in the periphery (Kaufmann et al., 1996). As
discussed earlier, COX-2 has been suggested to be involved in maintaining normal brain
homeostasis as well as in injury response. Its function as a physiologic intracellular modulator
of signal transduction leading to long-term potentiation and plasticity (Yamagata et al., 1993,
Kaufmann et al., 1996) may, on the other hand, allow it to behave as a deleterious mediator
under other circumstances (Adams et al., 1996). The immediate early gene COX-2, expressed
exquisitely by neurons with a relatively prolonged mRNA induction ranging from 30 min up
to 8 to 24 h (Adams et al., 1996, Kaufmann et al., 1996), may represent at first a rapid and
transient response to tissue damage, with its delayed (more substantial) response launched
through an excessive presynaptic glutamate release leading to subsequent COX-2 enzymatic
activity (Adams et al., 1996) (Figure 10). The latter may aggravate excitotoxic cell death and
coexist with the extracellular proinflammatory consequences of COX-2 activity (Yamagata et
al., 1993, Breitner et al., 1996). The prostanoids may exacerbate tissue injury through
vasoconstrictive, prothrombotic, chemoattractant, or direct neurotoxic action (see Chen et al.,
1995). Cerebral cyclooxygenase activity not only generates prostanoids, but also eventually
fuels generation of reactive oxygen species as byproducts in the reaction (Kontos et al., 1980,
Hall et al., 1993). The pro-inflammatory prostanoids and possibly also reactive oxygen
species produced by COX-2 have been suggested as mediators of NO neurotoxicity in
ischemic brain injury, because NO generated by inducible NO synthase (iNOS) potentiates
COX-2 activity in transient (Nogawa et al., 1998) and permanent focal ischemia (Nagayama
et al., 1999). Only prostaglandin production was evaluated in these studies, not free radical
levels, but the authors speculated that NO is a prerequisite for COX-2 neurotoxicity (Nogawa
et al., 1998, Nagayama et al., 1999).
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The second messengers involved in intracellular COX-2 induction remain
incompletely defined. In macrophages/monocytic cells, lipopolysaccharide (LPS) -induced
COX-2 gene transcription through promoter elements for NF-κB, nuclear factor IL-6 (NF-
IL6), and/or cyclic AMP-responsive element (CRE) was achieved redundantly by several
extranuclear kinase signaling pathways thus resulting in synergy (Mestre et al., 2001).
Emerging evidence supports NF-κB to be fundamental in COX-2 transcription in the aging
brain (Lukiw and Basan, 1998). Both TNF-α and IL-1β are known to induce COX-2 (Feng et
al., 1995). These cytokines induce NF-κB (Hsu et al., 1995, Barger et al., 1995), and they are
also induced by NF-κB, thus establishing an autoregulatory feedback loop (Kopp and Ghosh,
1995). Induced COX-2 gene expression may lead to deleterious amplification of prostanoid
production in addition to enhanced free radical production through COX-2 enzymatic activity
(Feng et al., 1995). On the other hand, centrally administered PGE2 has shown bidirectional
effects on vascular and microglia-associated responses induced by intracerebroventricular
LPS, since PGE2 increased LPS-induced NF-κB activity and COX-2 transcription in vascular
elements, but it reduced microglial activation and TNF-α expression in the brain parenchyma
(Zhang and Rivest, 2001).
Despite reduced prostaglandin production by the COX-2 selective antagonist in focal
cerebral ischemia (Nogawa et al., 1997, Hara et al., 1998), reduced infarct volume was not
evident in the latter study during a short reperfusion period of 4 h, differing from the longer
reperfusion in the former study. This supports a role for COX-2-generated prostaglandins in
the later propagation of ischemia-induced injury. Interestingly, the COX-2 selective inhibitor
has been shown to be more potent in improving survival of hippocampal neurons following
global cerebral ischemia than was the unselective antagonist (Nakayama et al., 1998). The
mechanisms after global cerebral ischemia leading to delayed neuronal death in the
hippocampus were suggested to be inherent to the neurons instead of the secondary effects of
prostaglandins on cerebral blood flow and inflammation which possibly are operative in focal
ischemia. Similarly, it has been speculated in AD that low doses of NSAIDs, without an anti-
inflammatory effect, may be neuroprotective by directly affecting neuronal activities
independent of glial/inflammatory activity (Breitner, 1996, Pasinetti, 1998). Figure 10 sums
up suggested brain ischemia-induced COX-2 expression due to immediate induction (minutes
to hours) and due to late induction (hours to days).
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Cytokine and iNOS-induced COX-2 Immediate induction of COX-2
     (in several hours to days)        (in minutes to hours)
Figure 10. Putative COX-2 activation during brain ischemia. Suggested inducers of COX-2
activation are in italics; left side depicts immediate induction in minutes to hours and right side shows
delayed induction by hours to days. The enzymatic reactions are shown with solid, curved lines.
Feedback induction of proximal factors by distal mediators is shown with a thin broken line. The
resulting intermediates are in the middle and their suggested functions at the bottom; their net result is
either neuronal death or promotion of survival. Abbreviations: IL-1β = interleukin-1β. TNF-α = tumor
necrosis factor-α. IL-1R = IL-1 receptor. TNFR1 = type I TNF receptor. NO = nitric oxide. iNOS =
inducible NO synthase. NMDA = N-methyl-D-aspartate glutamate receptor. PLA2 = phospholipase A2.
AA = arachidonic acid. NF-κB = transcription factor nuclear factor-kappa B. LTP = long term
potentiation.
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SUMMARY OF THE STUDY
5. AIMS OF THE STUDY
The search for other stroke therapies besides thrombolysis has inspired a vast body of
basic science research on molecular pathophysiological mechanisms of cerebral ischemia.
The description of possible mediators of ischemic brain damage has resulted in successful
experimental treatments that await proof of effectiveness and tolerability in humans. This
highlights the need to test the relevance of proposed pathophysiological mediators in the
ischemic human brain in addition to a more detailed description of these mediators in the
experimental settings.
The specific aims of this study were:
1. In rat global cerebral ischemia, to describe IL-1β and its signal transducing receptor
(IL-1R; Type I) mRNA and protein expression in ischemic brain damage at the
cellular level (I).
2. In rat cerebral ischemia, to describe expression of TNF-α mRNA and localization of
TNF-α protein in addition to the TNF receptor type I (TNFR1) that is suggested to
mediate cell toxicity (II and III).
3. In rat global ischemia, to correlate ischemia-induced changes in TNF-α and TNFR1
gene and protein expression with a known immediate early gene, c-fos (II).
4. In infarcted human brains, to describe localization of TNF-α protein and correlate it
to a marker of apoptotic cell death, namely TUNEL-staining (III).
5. In infarcted human brains, to describe the expression of COX-2 in relation to a stress
response protein, heat shock protein (HSP 72/73) during infarct maturation (IV).
6. To correlate findings from experimental ischemia models with ischemia-induced
changes in TNF-α and COX-2 expression in infarcted human brains (III-IV).
6. MATERIALS AND METHODS
6.1.  Experimental animals (I-II)
Twenty-six 16-week-old (275-470 g; mean 358±53.0 g) male Sprague-Dawley rats
(Taconic Farms, Germantown, NY, USA) were used for the study. The experiments reported
were conducted according to the principles set forth in the Guide for Care and Use of
Laboratory Animals, Institute of Laboratory Animal Resources, National Research Council
(DHEW publication No. NIH 85-23, 1985).
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6.2 Global ischemia model (I-II)
Transient forebrain ischemia was produced in rats as described by Smith et al.
(1984a). In brief, ischemia was achieved by bilateral carotid artery clamping for 20 minutes
combined with hypotension by blood withdrawal, followed by reperfusion. The rats were
anesthetized with 1 to 2% halothane and a 30/70 mixture of 02 and N2O. The CBF was
measured on-line by laser Doppler flowmetry according to a technique described earlier by
Lindsberg and colleagues (1991). The volume of blood withdrawn through a catheter placed
in the left femoral artery was adjusted to maintain CBF values below 10% of the baseline
value. Blood gas analyses were performed repeatedly on nearly half the animals. The pH was
corrected routinely by sodium bicarbonate (75 mg/ml) iv. Mean arterial blood pressure was
recorded for all experimental animals. Five sham animals underwent the same surgical
procedures except for the occlusion of the carotid arteries and systemic hypotension. The
animals were killed with an overdose of pentobarbital at 2 h (n=7), 8 h (n=7) or 24 h (n=7) of
reperfusion. The sham animals were killed at 24 h. Transcardial perfusion with precooled
phosphate buffered saline (PBS) for 4 to 5 minutes was completed before the removal of the
brain, which was immediately frozen and stored at -70° C until examined.
Coronal sections (18 µm) of the frontal lobe at the level of striatum and hippocampus
were cut in a cryostat for histological assessment (Figure 11).
 A)       B)
Figure 11. Rat brain structures at the level of striatum (A) and hippocampus (B). Illustrations of
brain structures analyzed in histological studies. Gray arrows and arrowheads depict brain areas
investigated. Abbreviations: CA1, CA2, CA3/CA4 areas and dentate gyrus of the hippocampal
formation (Modified from G Paxinos and C Watson: The rat brain in stereotaxic coordinates, 2nd
Edition, San Diego, Academic Press, 1986).
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6.3 Autopsy material (III-IV)
Autopsy specimens studied were from 16 cases of fatal ischemic stroke (symptom
duration from 15 h to 18 d) treated at the Department of Neurology, Helsinki University
Central Hospital. Autopsies were performed within a mean 17 hours after death (range, 3.5-45
h). Three patients who died of a non-neurological cause served as controls (III). Additional
control specimens were collected from patients (n=3) undergoing epilepsy surgery (IV). At
autopsy, approximately 1-cm3 cortical samples including subcortical white matter were
dissected, frozen in liquid nitrogen, and stored at -70°C until analyzed. Fresh-frozen sections
(5 µm) were cut and stained with hematoxylin-eosin to confirm ischemic neuronal changes.
Samples from corresponding areas of the contralateral or non-infarcted hemispheres and from
the control brains were processed in a similar way. The study protocol was approved by the
appropriate ethics committee of the Helsinki University Central Hospital. Table 4 shows
characteristics of the patients. Spontaneous, complete recanalization was absent from all cases
of thromboembolic infarction. Furthermore, in two patients who received 1.1 mg/kg of
alteplase (rt-PA) according to the European Cooperative Acute Stroke Study (ECASS) trial
protocol, no recanalization was achieved (cases 3 and 5; Table 4).
Estimation of the severity of neuronal ischemic changes from hematoxylin-eosin
staining was performed by a neuropathologist unaware of the patient history or the sample
localization. Focusing on the integrity of the nucleus, scores for signs of ischemic neuronal
changes in each tissue section were as follows: 0, normal morphology = sharply delineated
nuclei that can be differentiated from surrounding cytoplasm. 1, largely normal morphology
but scattered neurons with nuclear abnormalities such as pyknosis, low nuclear cytoplasmic
contrast, or smearing of nuclear border (similar to type III neurons by Eke et al., 1990). 2,
large proportion of neurons with nuclear abnormalities as mentioned for score 1. 3, large
proportion of neurons with nuclear abnormalities, with scattered ones exhibiting signs of
irreversible damage such as shrunken cytoplasm with irregular borders and invisible nuclei
(similar to type IV neurons by Eke et al., 1990). and 4, large proportion of neurons with
irreversible changes as mentioned for score 3. In the analysis of immunohistological stainings,
scores of 0 to 1 represented contralateral or control areas, scores 2 to 3 periinfarct area, and 4,
ipsilateral infarct core.
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Table 4. Characteristics of deceased stroke patients studied post mortem.
Case no*/
Gender
Age,
y
Risk factors 1 Cause of death 2
Agonal phase †
Survival
time
Occluded
vessel 3
HT 4
Medication
Prior/in-
hospital 6
1/M 63 AF, AS, DM, H, HF VF, Stroke 15h ICA/TE ASA/-
2/F 89 AF, CAD, DM, H Stroke 23 h MCA/E
HT
ASA/-
3/F 75 H Herniation 1d 4h MCA/T
Ht
-/Heparin,
Altepl.
4/F 67 CAD, HC, IE Herniation 1d 14h MCA/TE
Ht
ASA/NSAID
5/M 71 AF, AS Herniation 1d 19h ICA/TE -/Altepl.
6/M 82 None Herniation 2d 12h ICA/T -/NSAID,
Heparin
7/M 74 AS, CAD Stroke † 2d 12h BA/T
HT
ASA/-
8/F 79 CAD, H, HF PE (AMI, VF),
Stroke
3d MCA/T -/-
9/F 72 AS (EA), CAD Herniation 3 d MCA/T ASA/NSAID,
Heparin
10/M 46 AS 5 Stroke † 3d 6h BA/T -/-
11/M 55 None Stroke, PE 4d 12h ICA/T
Ht
NSAID/ASA,
NSAID
12/M 48 HC Stroke †, 7 5d 9h MCA/T ASA/-
13/F 66 None Stroke, PE 6d 7h BA/T NSAID/
Heparin
14/F 65 CAD, H, HF Stroke 8d 12h BA/T ASA, NSAID
/Heparin
15/F 75 AF, AS, CAD, DM, H PE, Stroke 17d ICA/T
Ht
-/Heparin,
warfarin
16/M 79 AF, CAD, H, HF PE, Stroke 18d MCA/TE
HT
NSAID/-
A/M 61 DM, H, HF CA - - NA
B/M 41 CAD 5 Duodenal ulcer - - NA
C/M 60 AS, CAD, HF, IE AMI - - NA
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* Cases A, B, and C, control patients dying suddenly without a neurological cause.
1
 Abbreviations for risk factors: AF = atrial fibrillation, AS = generalized arteriosclerosis, CAD = coronary artery
disease, DM = diabetes mellitus, EA = carotid endarterectomy, H = hypertension, HC = hypercholesterolemia, HF =
heart failure, IE = chronic ischemic encephalopathy.
2
 Abbreviations for cause of death: VF = ventricular fibrillation, herniation = herniations of brain, CA = cardiac arrest,
AMI = acute myocardial infarction, PE = pulmonary embolism. Immediate cause of death is given first and contributing
cause as second.
†
 Convulsions during agonal phase.
3 Abbreviations for occluded vessels: ICA = internal carotid artery, MCA = middle cerebral artery, BA = basilar artery,
T = thrombosis, TE = thrombo-embolism.
4 HT = hemorraghic transformation according to neuropathology report with HT referring to dense multifocal
hemorraghes and more subtle, local hemorrhages denoted by ht.
5
 Diagnosis based only on autopsy findings.
6
 Medications including acetosalicylic acid (ASA) or non-steroidal anti-inflammatory drugs (NSAID) prior to
hospitalization and in-hospital use of ASA, NSAIDs, thrombolytic agents (rt-PA; Alteplase = Altepl.), and/or
anticoagulants including heparin or low molecular weight heparins (Heparin) and warfarin.
7
 Contralateral MCA occlusion 7 months before
NA = not applicable
6.4. Blood and CSF sampling from the ischemic stroke cohort (III)
Severe or fatal ischemic stroke patients treated at the Department of Neurology of the Helsinki
University Central Hospital were recruited for peripheral blood sampling on day 1 (n=26, incl. 3 fatal), on
day 2 (n=7), on day 3 (n=7), and on day 4 (n=12) of hospitalization. Seven control persons were recruited.
They had no neurological syndromes (except one Parkinson’s disease) and were free of any history of
smoking, diabetes, or high blood pressure. CSF samples were obtained from 11 of the patients on day 1 of
hospitalization. The study protocol was approved by the ethics committee of the Helsinki University Central
Hospital.
6.5.  In situ hybridization (I-II)
In situ hybridization was performed to evaluate IL-1β and IL-1R (I) and TNF-α, TNFR1, and c-fos
(II) mRNA after global ischemia in a rat brain. The probes used were 30 or 45 base pair oligonucleotide
sequences complementary to the rat cDNA to mRNA sequences in the GenBank. The antisense
oligonucleotide sequences were as follows: 1) IL-1β: TGT GCC ACG GTT TTC TTA TGG CTC TGA
GAG, 2) IL-1 receptor: GTG TCC AGC ACA GGA TCC AGG GTT AAT AAG, 3) TNF-α: GCT GAG
CAG GTC CCC CTT CTC CAG CTG GAA, 4) TNF receptor: TCT GTG CTT GCC CCT ACC TTA GGG
AGT TCA, and 5) c-fos: GCA GCG GGA GGA TGA CGC CTC GTA GTC CGC GTT GAA ACC CGA
GAA. Sense probes of equivalent length contained a mirror image sequence of the antisense
oligonucleotides. An RNAse pretreatment was also included in the control experiments.
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Tissue sections were postfixed in 4% formaldehyde/PBS for 10 min. The sections were then
acetylated for 10 min with 0.25% (v/v) acetic anhydride and 0.1 M triethanolamine in sterile 0.9% (w/v)
NaCl (pH 8.0), dehydrated through graded ethanols, extracted with chloroform for 5 min, and rehydrated
through graded ethanols. The oligonucleotides were 3’-end labeled with [35S] dATP using terminal
deoxytransferase to a specific activity of approximately 5x106 cpm/ng. Hybridization was carried out
overnight in a humid chamber at 37°C in a volume of 100 µl of probe and hybridization buffer mixture, each
ml consisting of 500 µl 100% deionized formamide, 120 µl 5 M NaCl, 40 µl 2 M TRIS-HCL/100 mM
EDTA, 10 µl 10% Na pyrophosphate, 20 µl 10% SDS, 200 µg heparin, 200 µl 50% dextran sulphate, 20 µl 5
M dithiothreitol (DTT) and 80 µl of labeled probe, plus sterile water to arrive at 1x106 cpm/slide. After
hybridization the slides were washed at 42°C with four changes in 50% formamide in 2xSSC for 1 h and
with 2 changes in 1xSSC for 1 h. Hybridized radioactivity was visualized by coating the slides with Kodak
NTB2 or NTB3 emulsion for 2 to 4 weeks prior to exposion and counterstaining either with hematoxylin and
eosin or with cresyl violet.
The slides were examined under a light microscope. The number of positive cells was counted in a
field of an area of 0.152 mm2 and the mean number of positive cells was based on counting 2 or 5
fields/brain area in each animal. An arbitrary cutting point of > 45 silver grains per cell (with 500x
magnification) was chosen to represent positive cells, as this clearly exceeded background signal.
6.6. Immunohistochemistry (I-IV)
The primary antibodies used in immunohistochemistry and in double-immunofluorescent labeling
are summarized in Table 5.
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Table 5. Primary antibodies used in immunohistochemistry and in double-labeling immunofluorescence.
Publication Antiboby Dilution/incubation time Manufacturer
I 1) Pc rabbit anti-rat IL-1β 1:100/overnight Cytokine Sciences, Inc.,
Boston, MA, USA
I 2) Pc rabbit anti-mouse IL-1R 1:1000/overnight Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA
II 3) Pc rabbit anti-mouse TNF-α 1:2000/overnight Genzyme Corp., Cambridge,
MA, USA
I and II 4) Rabbit immunoglobulin G (R IgG) as
control for antibodies 1 to 3
1:100 to 1:2000/overnight Endogen Inc., Cambridge,
MA, USA
I 5) MoAb mouse anti-bovine microtubule-
associated protein-2 (MAP-2)
1:4000/overnight Boehringer Mannheim
II 6) Pc goat anti-mouse TNFR1 (G-20) 1:750/overnight Santa Cruz Biotechnology
II 7) Pc goat anti-mouse TNFR1 (E-20) 1:750/overnight Santa Cruz Biotechnology
I and II 8) MoAb mouse anti-rat CD11b (OX-42) 1:1000/overnight Serotec, Washington DC, USA
I and II 9) MoAb mouse anti-rat
myelin/oligodendocyte (MAB328)
1:1000/overnight Chemicon International, Inc.,
Temecula, CA, USA
I and II 10) MoAb mouse anti-glial fibrillary
acidic protein (GFAP)
1:500/overnight Boehringer Mannheim,
Indianapolis, IN, USA
I and II 11) MoAb mouse anti-rat perivascular
monocytes/macrophages (ED2)
1:1000/overnight Serotec
I and II 12) Control antibodies for monoclonals 8
to 11 were of the same immunoglobulin
(sub)class
1:500 to 1:4000/overnight Several manufacturers
II 13) Pc rabbit anti-cow GFAP 1:50/1 h Dako A/S
III 14) Pc rabbit anti-human TNF-α (IP-300) 1:100/1 h Genzyme Diagnostics
IV 15) Pc rabbit anti-human prostaglandin H
synthase
1:100/1 h Cayman Chemicals Co., Ann
Arbor, MI, USA
III and IV 16) Normal rabbit serum as control for
antibodies 14 and 15
1:100/1 h
IV 17) MoAb anti-heat shock protein 72/73
(HSP72/73)
1:100/1 h Boehringer Mannheim
Biochemica, Germany
III and IV 18) MoAb mouse anti-GFAP 1:25/1 h Dako A/S
III and IV 19) MoAb mouse anti-neurofilament 200
kDa (NF-200)
1:50/1 h Boehringer Mannheim
III 20) MoAb anti-CD15
epitope on granulocytes
1:50/1 h Dako A/S
Abbreviations: Pc = polyclonal antibody (Ab). MoAb = monoclonal Ab. When not given first in full, the abbreviations
in the parentheses refer either to the epitope recognized by the Ab (5, 8-11, 17, 19) or are catalogue numbers of the
manufacturers (6-7 and 14).
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Sections from rat brains (I-II) were postfixed for 30 min in 4% formaldehyde/PBS before incubation
in 0.3% triton X-100/PBS for 20 min. After 30 min incubation in 1% hydrogen peroxidase (H2O2)/0.3%
triton X-100/PBS to block endogenous peroxidase activity, the slides were blocked with 10% normal
serum/PBS for 1 h. After 20 to 24 h incubation of the sections with the primary antibody at +4°C,
amplification of the signal was carried out by the avidin-biotin (ABC) method with the appropriate
peroxidase kit as suggested by the manufacturer (Vector Laboratories, Inc., Burlingame, CA, USA) and
visualized by 4 min incubation in diaminobenzidine (DAB; Sigma Chemical Co, St. Louis, MO, USA) with
6 mg/0.0003% H2O2/10 ml PBS before investigation under a light microscope.
In human tissues (III and IV), acetone-fixed fresh-frozen sections were permeabilized in 0.3%
Triton-X for 20 min before quenching in 1% H2O2 and blocking with 10% normal sera for 1 h with PBS
washes in between. The chromogen aminoethylcarbazole (AEC; Sigma Chemical Co.) was used to visualize
the avidin-biotin complex/horseradish peroxidase signal according to manufacturer’s protocol (Vectastain
Elite Kit; Vector Laboratories, Inc.).
Control experiments included omission of the primary or secondary antibody in the ABC-method (I-
IV), preadsorption of the antibody with 10x (weight) excess of accompanying control peptide for rat IL-1R
(I) and for TNFR1(II), or preadsorption with a recombinant rat IL-1β (R&D Systems Inc., Minneapolis, MN,
USA; I), recombinant rat TNF-α (Biosource Int., Camarillo, CA, USA; II), or recombinant human TNF-α
(Genzyme Diagnostics; III) prior to immunostaining. Alternatively (IV) or additionally (I-III), specificity of
the antibodies was tested by Western blotting (6.9.).
6.7. Double-labeling immunofluorescence staining (II-IV)
After acetone fixation, blocking with 0.5% bovine serum albumin (BSA)/TBS for 5 min was
followed by permeabilization with 0.3% Triton-X100/PBS for 20 min. Incubation with TNF-α (1:50) or
TNFR-1 (1:75) antibodies (II), or COX-2 (1:50; IV), or TNF-α (1:50, III) antibody for 1 h was succeeded by
rhodamine-conjugated goat anti-rabbit TNF-α (II) antibody (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA, USA) at 1:40 dilution, or by a secondary biotinylated anti-goat antibody (TNFR-1; II) or by
biotinylated anti-rabbit (III-IV) antibody (Vector) and subsequent incubation with TexasRed®-conjugated
Neutralite avidin (A6377; Molecular Probes Europe BV, The Netherlands) at 1:200 dilution for 30 min.
Following these, cellular markers for neurofilaments, NF-200 kDa or NF-68 kDa antibodies (Boehringer
Mannheim GmbH; II-IV) were used at 1:50 dilution, and astrocytes were identified by rabbit anti-cow GFA
(Dako A/S, 1:50; II) or mouse monoclonal anti glial fibrillary acidic protein (Dako A/S) at 1:25 dilution for 1
h (II-IV). These were visualized with FITC-conjugated anti-mouse antibody (Dako A/S, Denmark) at 1:20
dilution for 30 min.
6.8. In situ cell death detection by TUNEL-labeling (III)
Double-labeling immunofluorescence detection of TNF-α and in situ cell death was carried out on
fresh-frozen brain sections. After 20 min fixation in formalin and blocking with 0.5% BSA/PBS, the sections
were permeabilized with 0.3% Triton-X/PBS for 20 min and they were incubated for 1 h with rabbit anti-
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human TNF-α antibody (IP-300, Genzyme Diagnostics) at 1:50 dilution. After incubation with biotinylated
anti-rabbit antibody (Vectastain Elite kit) at 1:200 dilution for 30 min and subsequent detection with
TexasRed-conjugated avidin (Molecular Probes) at 1:200 dilution for 30 min, the TUNEL reaction was
carried out according to manufacturer’s instructions (Boehringer Mannheim GmbH). Control sections were
incubated only with label solution. The washes included a rinse and two 10-min washes with PBS between
each step. After mounting and coverslipping, the sections were investigated with an epifluorescence
microscope.
6.9. Western blotting (I-IV)
For studies I and II, recombinants were diluted with reducing Laemmli sample buffer. In study II,
brain samples were crushed on dry ice and homogenated with a 5-fold volume of radioimmunoprecipitation
assay (RIPA) buffer containing 0.3% Triton-X100 and 0.1 mM PMSF in PBS. The samples were frozen
(-70°C) and thawed twice. A centrifuge run with 12000 rpm for 45 min at +4°C was followed by dilution of
the supernatant with reducing Laemmli buffer. For study IV, fibroblasts were incubated either with or
without interleukin-1 (10 ng/ml) for 6 h before lysis with a 5-fold volume of modified RIPA-buffer
(containing 150 nM NaCl, 1% NP-40, 0.1% SDS, 50 nM Tris (pH 8.0), 0.5 mM PMFS, 0.5% Triton-X 100,
and 1mM EDTA) and subsequent boiling for 5 min. After centrifugation at 2000 g for 30 min at +4°C,
supernatants were diluted with reducing Laemmli buffer.
Electrophoretic separation on a 15% (rat IL-1β, I, and human TNF-α, III), 12% (rat TNF-α, II), and
8% (TNFR1, II, and COX-2, IV) sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) was applied with
subsequent transfer to a nitro cellulose filter (Schleicher & Schnell, Germany). After blocking with 5%
BSA/TBS for 24 h and subsequently with appropriate normal serum (1:2000-1:3000) for 1 h, the filters were
incubated with the primary antibody of interest at +4°C overnight. This was followed by incubation with
anti-rabbit IgG peroxidase conjugated secondary antibody (Boehringer Mannheim) for TNF-α antibody (II)
or with secondary antibody plus ABC-amplification for other primary antibodies (I-IV) as described in the
section on immunohistochemistry (6.6.). Three washes with 1% Tween-20 in TBS were performed between
all the steps. An enhanced chemiluminescence (ECL) signal was exposed on an x-ray film and subsequently
analyzed with NIH Image Analysis software (I, III-IV). Parallel incubation of the filters with NRS (I, III-IV)
or a preabsorption control (II) was applied.
The primary antibodies tested for specificity after electrophoresis and blotting: 1) Two commercially
available polyclonal anti-IL-1β antibodies (from Endogen, 1.8 µg/ml, and R&D Systems, 16.7 µg/ml) were
used concomitantly with the antibody used for immunohistochemistry (2 µg/ml) to detect a dilution series of
recombinant rat IL-1β (R&D Systems) (I). 2) Detection of TNFR1 (at antibody dilution 1:3000) and TNF-α
(1:5000) from rat brain homogenates and a dilution series of recombinant rat TNF-α (Biosource Int.)
detected by the latter antibody (II). 3) Detection of a dilution series of human recombinant TNF-α
(Genzyme) by TNF-α antibody at 1:250 dilution (III). 4) Detection of a COX-2 signal from fibroblasts
stimulated with interleukin-1 in duplicate western blotting experiments (antibody dilution 1:1000) (IV).
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6.10. Northern blotting (IV)
Cytoplasmic total RNA was isolated from human brain tissue by the guanidine isothiocyanate-
cesium chloride method (Chirgwin et al., 1979). Three to 17 µg of RNA was denatured in 1 M glyoxal, 50%
dimethylsulfoxide, and 10 mM phosphate buffer at 50°C for 60 min and then electrophoresed through 1.2%
agarose gel before transfer onto Hybond-N nylon membranes (Amersham Int., Aylesbury, UK). Membranes
were then baked for 1 h at 80° C and cross-linked by UV light for 6 min. Human COX-2 and GAPDH
cDNAs (Ristimäki et al., 1994) were labeled using [α32P] dCTP (DuPont-New England Nuclear, Boston,
MA, USA) and the Prime-a-gene kit (Promega, Madison, WI, USA). Probes were purified with nick columns
(Pharmacia) and used at 1x106 cpm/ml. After hybridization at 42° C for 16 h in solution containing 50%
formamide, 6x SSC, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1% BSA, 100 µg/ml herring sperm DNA,
100 µg yeast RNA, and 0.5% SDS, membranes were washed 3 times (50° C) for 15 min with 0.1x SSC and
0.1x SDS. Northern blots were visualized by autoradiography and quantified with NIH Image Analysis
software.
6.11. Immunofluorometric assay (III)
TNF-α content in serum and CSF samples was assayed immunofluorometrically (IFMA) at a
detection limit of 6 ng/l as described earlier (Turpeinen and Stenman, 1994). This is a solid-phase assay with
time-resolved fluorometric detection. In short, wells were treated with glutardehyde prior to coating with
streptavidin. The streptavidin was bound by a monoclonal anti-TNF-α antibody (clone 199, Boehringer
Mannheim) that was biotinylated before addition to the wells. This antibody bound TNF-α in the samples
added to the wells. Incubation with Europium-labeled monoclonal anti-TNF-α antibody (clone 195,
Boehringer Mannheim) was followed by enhanchement solution prior to detection of fluorescence for 1 s by
fluorometer.
6.12. Statistical methods (I-IV)
When obtaining numerical data, the statistical significance of the differences between the means of
the groups was estimated by one-way ANOVA followed by Dunnet’s post hoc test. Data sets that were not
normally distributed were analyzed with the Kruskall-Wallis test followed by Dunn’s multiple comparison
test. A p-value less than 0.05 was considered statistically significant.
7. RESULTS AND DISCUSSION
7.1. In rat global forebrain ischemia, upregulated mRNA expression for IL-1β and IL-1R is
accompanied by increased glial IL-1β immunoreactivity and neuronal IL-1R immunoreactivity (I).
Global cerebral ischemia with reperfusion acutely altered the expression of IL-1β and its receptor in
a number of ischemia-sensitive brain structures, such as the hippocampal pyramidal cell layers, and granular
cell layers of the dentate gyrus, cerebral cortex, and striatum. Whereas IL-1β mRNA expression was
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increased both in the aforementioned gray matter structures and in the white matter (Tables 1 and 2 in I; Fig.
12A and 12C), a coinciding significant increase in IL-1R mRNA was seen exclusively over neuronal cell
bodies of the hippocampus (Table 3 in I; Figs. 13A and 13C). The number of IL-1R protein-expressing
hippocampal neurons was not increased (91% of hippocampal neurons both in sham animals and after 8 h of
reperfusion), but the intensity of the immunoreactivity was clearly enhanced at the level of single cells
(Figure 3 in I; Figs. 13B and 13D). A tendency towards increased numbers of IL-1β immunoreactive glial
cells (mostly astrocytes) was evident at the level of the striatum, and it reached significance in the
hippocampal structures CA2 and dentate gyrus (Tables 4 and 5 in I; Figs.12B and 12D). An interesting
scenario occurs, where glial cells are incited to propagate IL-1β effects in the post-ischemic brain (IL-1β
expression in glia), the targets being the neurons (neuronal expression of IL-1R). Moreover, these changes
occur before ischemic morphological changes become evident in light microscopy (Figs. 13E-13F), thus
supporting a role for IL-1β in the cascade leading to neuronal death.
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Figure 12. Upregulation of interleukin-1β (IL-1β) mRNA and protein expression in the hippocampus after
transient global ischemia.
A) Data represent mean+SD of positive cells/field based on counting 2 (CA2) or 5 fields (other areas) per respective
brain area in the sham group, and after 2 h, 8h, and 24 h of reperfusion (n=16). Estimation is based on light microscopic
evaluation of the intensity of the mRNA signal (400x). Cells were considered positive when they showed >20 silver
grains per cell at a magnification of 256x. Abbreviations for brain areas: CA1 = CA1 region of hippocampal formation;
CA2 = CA2 region; CA3/4 = CA3 and CA4 regions; DG = dentate gyrus.
B) Mean number+SD of IL-1β immunoreactive cells with glial morphology in hippocampal regions. Numbers represent
mean+SD of immunoreactive glial cells/field determined by counting 2 (CA2) or 5 fields (other areas) per brain area in
sham and post-ischemic animals (n=16) under light microscope. Note the difference from mean numbers in A) which
include both glial and neuronal IL-1β mRNA-expressing cells.
C) Composite image of IL-1β mRNA expression in a sham hippocampal CA 1region (left side) in comparison to
maximal mRNA expression after 8 h reperfusion (right side). Note clustering of silver grains mostly on top of neuronal
somas after reperfusion. Magnification 256x original; the bar represents 40 µm.
D) IL-1β immunoreactivity in the hippocampal CA1 region in a sham brain (left side) as compared to increased number
of these glial cells after 24 h reperfusion (right side). Magnification 400x, bar represents 40 µm.
* p<0.05 and ** p<0.01 determined by one-way ANOVA and Dunnet’s pot hoc test
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Figure 13. IL-1 Receptor (IL-1R) mRNA expression and immunoreactivity in different hippocampal regions
after global ischemia.
A) Numbers represent mean+SD of IL-1R mRNA-expressing cells/field determined by counting 2 (CA2) or 5 fields
(other areas) in each brain area in sham and post-ischemic animals (n=16) under light microscope (400x). Cells were
considered positive when they showed >20 silver grains per cell at magnification 256x.
B) Number of IL-1R immunoreactive neuronal somas was determined by counting 2 (CA2) or 5 fields (other areas) in
each brain area in sham and post-ischemic animals (n=16) under light microscope (400x) and is presented as mean+SD
of neurons/field showing IL-1R protein. Abbreviations for brain areas: CA1 = CA1 region of the hippocampal
formation; CA2 = CA2 region of the hippocampal formation; CA3/4 = CA3 and CA4 regions of the hippocampal
formation; DG = dentate gyrus of the hippocampal formation.
* p<0.05 and ** p<0.01 determined by one-way ANOVA and Dunnet’s pot hoc test.
C) Composite photomicrograph depicting IL-1RmRNA expression in the sham hippocampal CA1 area with occasional
positive neuronal somas (left side) as opposed to peak IL-1R mRNA expression clustering over neuronal somas of the
CA1 region after 2 h reperfusion (right side). Magnification 256x; bar represents 40µm.
D) IL-1R immunoreactivity in the CA1 region in a sham brain (left side). In the center, intensification of the staining by
2 h reperfusion is evident, despite no increase in number of IL-1R immunoreactive neurons (B). After 24 h reperfusion,
a patchy immunoreactivity pattern was detected in three out of four animals (right side). This is due to loss of IL-1R
positive neurons. Magnification 400x; bar represents 40µm.
E) Overview of a sham hippocampus stained with Cresyl violet with a high-power insert showing CA1 pyramidal
neurons.
F) No obvious drop-out of hippocampal neurons was evident in another brain after 24 h reperfusion, but the high-power
insert shows subtle early ischemic transformation (rarefication and pale cytoplasm) of the pyramidal CA1 neurons.
Changes in IL-1R mRNA and protein expression thus occurred prior to gross ischemic morphologic changes. Bar
represents 40 µm in high-power inserts in E-F.
The low or absent sham expression of IL-1β mRNA described in scattered cells in our study is in
line with earlier findings of low basal expression detected from normal rodent brains by PCR (Higgins and
Olschowka, 1991) or by in situ hybridization (Bandtlow et al., 1990). No basal expression for IL-1β mRNA
was detected in an earlier in situ hybridization study when quantitating the autoradiographic signal (Buttini et
al., 1994) or in Northern blot of sham brains (Minami et al., 1992, Liu et al, 1993). This probably correlates
with the lower sensitivity of in situ hybridization analysis when performed from autoradiograms as opposed
to analysis at cellular level (light microscopy), and the lower sensitivity of the Northern blot-method to
detect subtle mRNA expression. The early induction of the IL-1β mRNA signal in post-ischemic brains has
been a uniform finding in earlier studies (Minami et al., 1992, Liu et al., 1993, Buttini et al., 1994, Yabuuchi
et al., 1994, Wang et al., 1994, Szaflarski et al., 1995, Zhai et al., 1997) and was confirmed by us. The
limited number of descriptions on cellular localization of ischemia-induced expression of IL-1β mRNA
reveal a topography similar to ours, but they suggest mostly glial origin of the mRNA signal (Buttini et al.,
1994, Yabuuchi et al., 1994). Our suggestion of a mostly neuronal origin of ischemia-induced IL-1β mRNA
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in the cortex and hippocampus is in line with reports on normal brain, where hippocampal IL-1β mRNA
expression was suggested to be neuronal by morphological criteria (Bandtlow et al., 1990) and with the
descriptions of IL-1β protein in neuronal processes both in the rodent hippocampus (Lechan et al., 1990) and
human brain (Breder et al., 1988).
The distribution of IL-1β immunoreactivity in sham brains is similar to the mRNA expression
described by Bandtlow and coworkers (1990). The main cell-type of IL-1β immunoreactivity was identical
to GFAP-positive astrocytes, as described in later studies as well (Orzylowska et al., 1999, Knerlich et al.,
1999), and additional identity was observed with scattered oligodendrocytes, perivascular macrophages, and
sporadic migroglial cells. Although the possibility that some of the cellular processes in the hippocampal
area to represent IL-1β immunoreactivity in neuronal processes cannot be ruled out (Lechan et al., 1990), IL-
1β immunoreactivity was not seen in structures that stained with the cellular markers for neuronal cell bodies
and dendrites (microtubule-associated protein-2) or for endothelial cells (von Willebrand factor). Recent
studies with PMCAO confirmed areas of IL-1β protein expression similar to ours. Microglia and
macrophages were suggested as the major source of immunoreactivity (Zhang et al., 1998, Davies et al.,
1999), with additional immunoreactivity found in endothelial cells bilaterally (Zhang et al., 1998). In neither
study was neuronal immunoreactivity detected. Yet, confirmation of the cellular origin of post-ischemic IL-
1β protein requires additional double-labeling studies in different experimental paradigms (reperfusion or
not, global vs. focal ischemia).
The distribution of sham IL-1R mRNA expression described in our study is in line with results from
IL-binding assays (see in Rothwell, 1991) and in situ hybridization studies (Cunningham et al., 1992, Yan et
al., 1992) supporting mostly neuronal expression of IL-1R. Furthermore, our study shows post-ischemic
neuronal IL-1R protein immunoreactivity in the cortex and hippocampus (Fig. 13D) besides sporadic
immunoreactivity in the white matter and vascular structures, an apparently novel finding not yet described
by others.
The discrepancy between the increase in the number of IL-1R mRNA-expressing cells and no
increase in the number of IL-1R immunoreactive cells may have several reasons. It may be due to
downregulation of the IL-1 receptor synthesis by IL-1, as has been described for murine Th2 cells. The
mechanism is a decrease in the half-life of the mRNA for IL-1R (Dinarello, 1991). Furthermore, low
receptor occupancy is suggested to be enough for triggering intracellular signaling by IL-1 in T cells and thus
favors the idea of less pronounced receptor protein expression still to be effective (Dinarello, 1991). The
discrepancy may also be due to inhibition of protein synthesis in ischemic tissue. In a compromised energy
state, the neurons may be able to transcribe mRNA for IL-1β and IL-1R, but lack the capacity to translate
these to actual proteins, due to reduced overall protein synthesis. The reduction in protein synthesis is
suggested to be transient in cells that recover from the insult (glial cells being more resistant than neurons),
but to be sustained in the cells destined to die (Thilmann et al., 1986). Our findings are also in keeping with
the hypothesis that IL-1β participates in the mediation of selective neuronal death, since IL-1β was translated
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to protein in the hippocampal glial elements residing next to IL-1R immunoreactive neurons. Moreover, this
occurred prior to light microscopic neuronal damage. In the hippocampus, also glial translation to protein
may have been modulated by the depth of ischemia, as it was evident in the dentate gyrus (least sensitive to
ischemia) and CA2 (reactive change due to ischemia) with no increase in translation in the most sensitive
CA1 region of the hippocampus containing the cells that are destined to die (Kirino and Sano, 1984).
7.2. In rat global forebrain ischemia, upregulation of TNFR1 mRNA and immunoreactivity is detected
in neurons, glial and endothelial cells in addition to upregulated TNF-α mRNA in gray and white
matter structures and increased TNF-α immunoreactivity in oligodendroglial cells (II).
TNF-α mRNA was transiently upregulated in gray and white matter regions, peaking after 8 h of
reperfusion (Fig. 14B). Cortical TNFR1 mRNA was already induced at 2 h of reperfusion, and its expression
was maximal in striatal and hippocampal structures at 8 h (Figure 1 in II; Fig. 14E). Transient upregulation
of TNF-α and TNFR1 mRNA was demonstrated mainly in neurons, a novel finding that complements the
detection of neuronal TNF-α mRNA in a normal mouse brain (Hunt et al., 1992) and that of TNF-α and
TNFR immunoreactivity in the neurons of the ischemic penumbra and infarct core after focal ischemia (Liu
et al., 1994, Botchkina et al., 1997). In agreement with previous reports, we detected neuronal c-fos mRNA
peaking after 2 h of reperfusion (Figure 1 in II; Fig. 14A) (Jørgensen et al., 1989, Akins et al., 1996, Wang et
al., 1994). The temporal and topographic association of c-fos and TNF-α in the present study supports c-fos
in regulation of TNF-α mRNA expression in striatal and hippocampal neurons (Figs. 14A-B), whereas
molecular regulation of TNFR1 gene induction deserves further investigation, as the peak expression was
already reached after 2 h reperfusion (Fig. 14D). Yet other regulative mechanisms are likely to underlie
TNF-α mRNA regulation in glia (Figs. 14B and 14D), since no upregulation of c-fos gene was detected in
the white matter areas (Fig. 14A).
Tumor necrosis factor-α immunoreactivity was seen in neurons >>> oligodendrocytes = perivascular
cells = ependymal cells = vessel wall structures (Figures 3 and 5 in II). After ischemia/reperfusion, a
significant increase in the number of tumor necrosis factor-α immunoreactive cells was evident after 8 h
among oligodendrocytes. These were identical to MABP-staining for myelin/oligodendocytes of adjacent
section and they showed oval shape morphology and typical brain location; the TNF-α positive cells were
oval cells detected in rows in the corpus callosum (Fig. 14C). TNF receptor immunoreactivity manifested in
bundles of cellular fibers of variable length and thickness in sham brains. In post-ischemic brains,
immunoreactivity in these cellular processes, representing mainly astroglial extensions by double-labeling,
was suppressed at 2 h but recovered partially by 8 h and 24 h of reperfusion (Figures 5 and 6 in II).
Corresponding with mRNA changes, transient ischemia-induced upregulation of TNFR1 immunoreactivity
was observed already after 2 h in somas of large cortical neurons, in activated microglia/macrophages, in
perivascular, and in endothelial cells (Fig. 14F). All in all, this early increase in TNFR1 immunostaining
supports the role of TNF-α as a mediator of ischemic injury in these cell types. The role of increased
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immunostaining for TNF-α in oligodendroglia remains to be elucidated. Although the increase in their
number was detected in the white matter, it may be taken as an sign of increased immunoreactivity in
oligodendroglia in the gray matter as well; a double-staining would be required to confirm this. Indeed,
oligodendroglia in the cortex and thalamus have been reported to be selectively vulnerable to global ischemic
injury occurring prior to neuronal death that takes place after days (Petito et al., 1998). Moreover, co-
labeling for apoptotic cell death by in situ end labeling (ISEL) and by transferrin in oligodendrocytes
suggested oligodendroglial apoptosis to take place during the first day. Since TNF-α is a potent stimulus for
oligodendroglial death and apoptosis, the increased TNF-α immunoreactivity detected in our study may
reflect this pathway or it may be a sign of oligodendroglial TNF-α-signaling to the TNFR1-positive cells.
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Figure 14. Quantification of TNF-α, TNFR1, and c-fos mRNA expression at the striatal and
hippocampal level.
The number of positive cells/field of an area of 0.152 mm2 was counted under light microscope (40x
magnification) in five fields of each brain area. At the striatal level, these included cortex (Ctx.),
caudate putamen (C.p.), and corpus callosum (C.c.). At the hippocampal level, 1 to 5 fields were
investigated according to the size of each anatomical region, including CA1 (5 fields), CA2 (1 field),
CA3/CA4 (5 fields), and dentate gyrus (DG; 5 fields) of the hippocampal formation. Results are
presented as mean+SE of the mRNA-positive cells.
A) Quantification c-fos mRNA expression in different hippocampal areas in sham and post-ischemic
brains. Peak neuronal mRNA expression was already reached after 2 h reperfusion and thus preceded
the mRNA expression for TNF-α, peaking at 8 h (B). No increase in mean number of TNF-α
immunoreactive neuronal somas was evident in the cortex between sham (left side of image C) and
post-ischemic brain (right side of C). A significant increase in number of TNF-α immunopositive cells
in the corpus callosum was detected between a sham (left side) and post-ischemic brain (right side).
This mirrored the increase in TNF-α mRNA seen in the corpus callosum (B) that was not preceded by
c-fos induction (A). Thus the molecular mechanisms leading to increased mRNA expression of TNF-α
in the corpus callosum (B) and increased cortical TNFR1 mRNA already upregulated after 2 h
reperfusion (E) employ another IEG (D). Post-ischemic increase in TNFR1 immunoreactivity in
neuronal somas (upper panel in F; magnification 500x), in microglia/perivascular cells (center section
in F; 1500x), and in endothelial cells was evident (lower panel in F; 1500x) as compared with low or no
such immunoreactivity in sham brains (not shown). Bar represents 40 µm.
** p<0.01, as compared to sham group (Anova + Dunnett’s post-hoc test; Normality test passed)
* p<0.05, as compared to sham group (Anova + Dunnett’s or Kruskall-Wallis + Dunn’s multiple
comparison test; Normality failed).
We detected both TNF-α mRNA and immunoreactivity in sham-operated control
animal brains. In agreement with these results, TNF-α immunoreactivity has been reported in
neuronal fibers and neurons of normal murine brain (Breder et al., 1993, Gahring et al., 1996,
Ignatowski et al., 1997). Other studies have reported weak neuronal (Nawashiro et al.,
1997b), or ependymal and perivascular (Holmin et al., 1997) TNF-α immunoreactivity, or no
immunoreactivity (Hunt et al., 1992, Tchelingerian et al., 1993, Liu et al., 1994) in the brains
of normal or sham-operated animals. This discrepancy may be due to the different species
used (mice vs. gerbil vs. rat), to differences in tissue processing (brain perfusion, fixation
methods) or staining methods (including antibody related differences).
The apparent lack of concordance between neuronal TNF-α mRNA and protein
expression may be due to decreased mRNA stability in the ischemic brain. In addition, the
number of cells translating TNF-α mRNA to protein may not be increased, even though TNF-
α protein production by individual cells is increased. Moreover, we studied TNF-α expression
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after severe ischemia in brain areas where global post-ischemic reduction of protein synthesis
is known to injure especially neurons (Thilmann et al., 1986). A lesser degree of ischemic
insult might have permitted detection of a more robust increase in TNF-α immunoreactivity.
Indeed, increased TNF-α immunoreactivity has been previously described in the ischemic
hemisphere after focal ischemic brain injury in rodents (Liu et al., 1994, Buttini et al., 1996,
Uno et al., 1997) and also locally in the lesioned hippocampus of mice after kainic acid
injections (Bruce et al., 1996). In our paradigm of robust global ischemia/reperfusion,
ischemia-induced TNF-α immunoreactivity was seen in cells with oligodendrocyte
morphology only, which may contribute to ischemic brain injury due to the potent
cytotoxicity of TNF-α to oligodendrocytes (Selmaj and Raine, 1988). Additionally, a pool of
soluble TNF-α (Bemelmans, 1996) may escape detection by immunohistochemical staining
because of prior perfusion of the brain. In fact, an early increase in brain TNF-α
concentrations has been reported after transient global ischemia when TNF-α expression was
measured in unperfused brain homogenates (Saito et al., 1996, Uno et al., 1997). It is also
possible that an increase in TNF-α immunoreactive protein was not detected by antibody
staining, since the binding of TNF-α by the increased TNF receptor makes TNF-α
unavailable to the antibody. Other speculative theories as to why TNF-α mRNA was not
translated to protein may be that 1) TNF-α is not needed (not a survival factor), 2) TNF-α is
not wanted (harmful, a suppressor of protective agent-synthesis) or 3) TNF-α is protective,
but some blocking agent inhibits its synthesis in ischemia.
Our data on TNF-α and TNFR1 are of interest as data presently available from
interventions on TNF-α in ischemia are controversial. TNF-α has been shown both
neuroprotective and neurotoxic. Describing the cellular participants in ischemic injury in vivo
is of crucial importance for understanding the interwoven mechanisms of the whole brain.
Our finding that TNFR1 immunoreactivity in cellular processes is suppressed after 2 hours of
I/R may reflect post-ischemic downregulation of TNFR1 synthesis, or receptor shedding from
astroglial processes that could possibly serve a protective role against early deleterious TNF-
α effects by neutralizing soluble TNF-α. Transient and early microglial TNFR1
immunoreactivity supports that they respond to TNF-α and that they participate in injury
progression through release of additional cytokines, proteases, free radicals, and NO
(Gehrmann et al., 1995). The finding of TNF-α and TNFR1 immunoreactivity in vascular
structures (including perivascular cells) suggests inflammatory effects of TNF-α as further
participating in brain injury through endothelial pro-adhesive (Yang et al., 1998b) and pro-
coagulant transformation, leading to leukocyte migration in conjunction with increased
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protease activity and free radical formation (Hallenbeck, 1994, Gehrmann et al., 1995,
Dawson et al., 1996).
7.3. In human ischemic stroke, TNF-α immunoreactivity is multicellular and shows
partial overlap with TUNEL-staining during the acute phase of infarct maturation (III).
In human, cells throughout the brain contributed to increased TNF-α
immunoreactivity during the different phases of focal cerebral infarction with none or
incomplete recanalization (Figure 1 and Tables 1 and 2 in III). Neuronal TNF-α was
demonstrated by immunohistochemical staining from the acute phase (0.6-1.0 d) to up to 5.4
days after the onset of stroke symptoms, peaking bilaterally during days 2 and 3. Bilateral
TNF-α immunoreactivity was detected in astrocytes, in oligodendrocytes, and in microglial
cells during the first day. TNF-α immunoreactivity in astroglial cells dominated from the
third day on up to a week, and it persisted contralaterally to the infarction during more
matured phases (17-18 d). Additionally, invading inflammatory cells and sporadic vascular
wall structures showed TNF-α immunoreactivity. TUNEL-labeling and TNF-α staining
overlapped, although not completely, during the first days (Figure 2 in III; Figures 15A-B).
TNF-α levels measured by immunoassay were mostly non-detectable in peripheral blood
samples from the stroke cohort with severe and fatal cases.
The sustained, comprehensive cellular participation of TNF-α immunoreactivity in
human differs from that reported in experimental animals. In a paradigm most similar to our
human material, namely in permanent MCAO, TNF-α immunoreactivity was restricted to
microglial cells during the first 2 days (Buttini et al., 1996, Gregersen et al., 2000), with
bilateral expression described at the mRNA (Zhai et al., 1997) and protein level (Buttini et al.,
1996). Neuronal TNF-α immunoreactivity has been described to peak in 1 day in PMCAO
(Liu et al., 1994, Gong et al., 1998) in addition to immunoreactivity in astrocytes of the
periinfarct region (Botchkina et al., 1997, Gong et al., 1998, II). After global ischemia, the
source of TNF-α immunoreactivity were microglial cells during the first hours and after 3
days the main source were astrocytes, whereas no neuronal TNF-α immunoreactivity was
detected (Uno et al., 1997). Endothelial TNF-α immunoreactivity was detected (Uno et al.,
1997), but not analyzed systematically. Complementing our results, astroglial TNF-α
immunoreactivity has been described after chronic durations of ischemia in human brain
(Tomimoto et al., 1996).
TNF-α production was more prolonged in infarcted human brains than described
in most experimental stroke models, in which a decline in TNF-α mRNA and protein
has become evident by 12 to 24 hours of reperfusion (Wang et al., 1994, Szaflarski et al.,
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1995, Saito et al., 1996, Buttini et al., 1996, Uno et al., 1997, II). A more protracted
expression of immunoreactivity of up to 5 d has been described in permanent focal cerebral
ischemia in rodents (Liu et al., 1994). The extended time evolution of the TNF-α response in
man, peaking at 2 to 3 days after stroke, supports its potential role in the reorganization of
human cerebral infarcts. Taken together, with no increase in peripheral blood TNF-α content
in our study and in another clinical series (Fassbender et al., 1994), TNF effects are likely to
be restricted to the infarcted brain.
Our results are in accord with the description of the bulk of apoptotic cells as being
located in the periinfarct area, with some scattered cells found also in the infarct core (Li et
al., 1995). Furthermore, in human ischemic stroke, we established TUNEL-depicted cell
death to occur also in the contralateral hemisphere (Figures 15A-B) and co-existing with
TNF-α expression (Figure 2 in III). However, the incomplete overlap differs from the
previous finding in PMCAO in rat that only TUNEL-positive neurons express TNF-α inside
the first 24 hours (Botchkina et al., 1997). This discrepancy may be explained by the more
heterogenous human stroke material and multiple brain locations investigated in our study, or
may be due to species differences. TUNEL-labeling of dying cells without the presence of
TNF-α implies that other mechanisms regulate apoptotic cell death as well. The proportion of
cells dying through apoptosis as opposed to necrosis during different acute brain insults still
remains an open question, but the evidence so far suggests apoptosis as the cause of death of a
minority of dying cells (Linnik et al., 1993, Rink et al., 1995).
Figure 15. Double-fluorescent labeling with TNF-α (Texas Red) and TUNEL (FITC).
A) TNF-α fluorescence (arrow) was evident at 1.6 d after MCA occlusion and partially co-localized
with intensive TUNEL-labeling in cell nuclei (arrow in B). On the other hand, TUNEL-labeling was
present (arrowheads in B) without co-localization with TNF-α in the infarction core, periinfarct area,
and also in the contralateral hemisphere shown here (A-B). Bar 10 µm.
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Blocking TNF-α especially augments periinfarct microvascular perfusion deficits
(Dawson et al., 1996). The number of ICAM-1 immunopositive vessels in the ischemic area
was significantly reduced by TNF-α neutralizing antibody (Yang et al., 1998b). Furthermore,
TNF-α injection results in leukocyte adhesion to microvascular endothelium (Wright et al.,
1992, Yamasaki et al., 1992, Liu et al., 1994). Thus, the inflammatory and vascular actions of
TNF-α seem to be important in the pathophysiology of cerebral ischemia. Our results support
the occurrence of these phenomena also in infarcted human brain. The neuroinflammatory
activities of TNF-α have been demonstrated to be triggered by transmembrane-TNF on
astrocytes, not on neurons (Akassoglou et al., 1997). The role of neuronal TNF-α remains to
be determined.
It has been suggested that TNF-α is proinflammatory in the initial phase of infection
and later takes an anti-inflammatory or preparative role (Marino et al., 1997). A dual role for
TNF-α also in brain is supported by the finding that the maximum infarct area is reached by 6
h in PMCAO (Gregersen et al., 2000), yet TNF-α mRNA and protein are detectable after this
time-frame. This is in line with our results showing extended duration of TNF-α response in
infarcted human brains, thus supporting additional role for TNF-α besides initial participation
in injury propagation.
7.4. COX-2 is induced globally in infarcted human brain without temporal and
topographic correlation with heat shock response (IV).
Neuronal and glial COX-2 immunoreactivity was detected early (15-24 h) in the peer-
infarct areas and was subsequently (1.2-6.3 d) elicited prominently in the neurons and to a
lesser extent in glial cells of the infarct core and the contralateral hemisphere (Figure 2 in IV).
Thereafter, neuronal and endothelial COX-2 immunoreactivity (8.5-18 d) persisted
predominantly in the contralateral, surviving hemisphere (Figure 1 in IV; Fig. 16A). In
contrast, the majority of HSP 72/73 immunoreactivity as a marker of cellular stress was
detected in neurons (Figure 2 in IV), and less in glial and endothelial cells of the penumbral
areas of acute infarctions (Fig. 16B), which corresponds to observations in experimental
models (Kinouchi et al., 1993). However, our material is limited by the lack of even more
acute infarctions and does not reveal immediate changes in gene expression, which might also
involve more proximal induction of COX-2 as an IEG before the phenotypic correlates of cell
stress can be observed. The lack of temporal and topographic correlation between the heat
shock response and the evolving COX-2 expression indicates that COX-2 is not merely
responding to injury-related cellular stress, but represents a more globally regulated change in
the gene expression in focally infarcted human brain. Moreover, COX-2 was not transiently
induced, but persisted up to 2.5 weeks and therefore probably plays a more fundamental role
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in the face of graded tissue ischemia as well as remodeling of the injured brain. In
Alzheimer’s disease, differential roles have been suggested for synaptically regulated
neuronal COX-2 actions as opposed to glial COX-2 as a mediator of inflammatory reactions
(Breitner, 1996, Chang et al., 1996, Pasinetti, 1998). The balance of these actions may well be
applicable to infarct maturation as well.
A) Number of cyclooxygenase-2 (COX-2) immunoreactive neuronal processes in different brain
regions.
Figure 16. Cyyclooxygenase-2 (COX-2) and heat shock protein (HSP 72/73) immunoreactive
neuronal processes in control brains, in the ipsilateral and non-infarcted (basilar artery
occlusions) hemispheres of stroke cases.
Microscopic quantification of neuronal COX-2 was performed by counting COX-2 immunoreactive
cell processes identical to neurofilament-200-positive processes from five fields of 0.152mm2 from
each slide. Three to five slides per case were counted. An interrelated topographic grouping to
periinfarct and infarct core areas was based on the scoring of the relative severity of neuronal ischemic
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damage. Estimation of HSP 72/73 immunoreactivity was performed similarly in one to five slides per
case.
A) Mean+SE values of COX-2 immunoreactive neuronal processes in the different brain regions during
subsequent maturation phases of the infarction, including acute (0.6-1 d; n=2), subacute (1.2-6.3 d;
n=11), and chronic (8.5-18 d; n=3) infarctions. A comparison between the controls and subacute (1.2-
6.3 d) infarctions yielded statistically significant differences in the mean values of all brain regions
(p<0.05).
B) HSP 72/73 immunoreactivity in neuronal processes of the different brain locations is indicated as: -
no immunoreactivity in neuronal processes, + immunoreactive neuronal processes detected, and NT =
not tested. The text box below indicates HSP 72/73 immunoreactivity in other cell types in respective
brain locations.
Despite the fact that animal studies have suggested low constitutional expression of
COX-2 in discrete brain regions, including the neocortex (Yamagata et al., 1993, Planas et al.,
1995, Nogawa et al., 1997), our data supported this only at the mRNA level. At the protein
level, neuronal COX-2 was detectable in only one of the control brains. The expression of
COX-2 in normal human brain remains to be determined in a larger material. Also, a more
extended study combining mRNA and protein data is required to better describe the
transcriptional, posttransciptional, and translational regulation of COX-2 during the energy-
compromised state of brain ischemia in experimental animals and humans.
The suggested requirement of oxygen for the enzymatic activity of COX-2 (Gaudet et
al., 1980, Stevens and Yaksh, 1988) underlines the need to test the role of reperfusion in
COX-2 induction and therapeutic approaches that regulate it. Reperfusion per se has been
shown to increase brain infarct size and ibuprofen to reduce infarct size only when
reperfusion was allowed (Cole et al., 1993). On the other hand, it has been shown that COX-2
mRNA is induced also by permanent MCA occlusion (Collaço-Moraes et al., 1996, Kinouchi
et al., 1999) and that a COX-2-specific antagonist ameliorates ischemic brain injury after
PMCAO when given repeatedly over days (Nagayama et al., 1999). After permanent vascular
occlusion, it remains to be elucidated whether inhibition of COX-2 leads to reduced
prostanoid products besides altered generation of oxygen free radicals as a result from its
enzymatic activity. In transient MCAO, anti-inflammatory treatments have been shown to
reduce COX-2 immunoreactivity (Yrjänheikki et al., 1999) and prostaglandin production
(Nogawa et al., 1997). Whether reduced COX-2 expression is secondary to less pronounced
inflammatory reactions is unclear (Yrjänheikki et al., 1999).
The cellular sources of COX-2 in infarcted human brains were similar to those
detected in experimental animals (Nogawa et al., 1997, Miettinen et al., 1997). Moreover, our
present data on human brain infarction underscore the widespread and prolonged nature of
COX-2 response in clinical stroke, a phenomenon clearly different from the transient,
80
unilateral pattern reported in experimental animal models of focal and global ischemia (Planas
et al., 1995, Collaço-Moraes et al., 1996, Ohtsuki et al., 1996b, Miettinen et al., 1997,
Nogawa et al., 1997). A COX-2 immunoreactivity pattern complementary to our results is
evident in a later study focusing on more chronic human ischemic brain infarctions
(Tomimoto et al., 2000). Iadecola and colleagues (1999) reported neuronal COX-2
immunoreactivity only at the border of acute infarctions (within 1-2 days). Moreover, they
detected no immunoreactivity in distal neuronal processes, as opposed to our finding of
intensified COX-2 immunoreactivity in neuronal processes of post-ischemic human brains.
Differences in tissue preparation may account for this discrepancy. Their study was
performed on formalin-fixed paraffin-embedded sections, while we used fresh-frozen
acetone-fixed sections. Formalin fixation leads to variable masking of tissue antigens that
may be unmasked with microwave oven treatment (Merz et al., 1993) thus enhancing
sensitivity, although according to the recent literature this procedure does not seem to be
crucial for detection of COX-2 immunoreactivity. On the other hand, in frozen sections from
normal rat brains, sensitivity of COX-2 staining has been suggested to be a limiting factor,
since neurons with the most intense immunoreactivity exhibited distal dendritic COX-2
staining that could have been missed in less strongly positive neurons (Kaufmann et al.,
1996).
Taken together with the data suggesting that inhibition of prostanoid production is
therapeutically feasible during acute phases of brain ischemia (Hallenbeck and Furlow, 1979,
Clemens et al., 1991, Chen et al., 1995, Nogawa et al., 1997, Nakayama et al., 1998,
Nagayama et al., 1999), our present results on COX-2 expression extend the hypothesis to
human ischemic stroke. Since a more sustained expression of COX-2 was evident in the
infarction core and periinfarct areas in human brains (0-6 days), a wider therapeutic window
for antagonism of acute COX-2 production may be considered in the clinical situation without
disturbing possible reparative functions mediated by later induction of COX-2. This is also in
line with repetitive peripheral dosing of NSAIDs over three days to reduce brain infarct size
in experimental animals (Nogawa et al., 1997, Nagayama et al., 1999).
7.5. Relationship and possible roles for IL-1β, TNF-α, their receptors, and COX-2 in
brain ischemia (I-IV).
As demonstrated in experimental stroke models, cerebral ischemia induces immediate
early genes such as c-fos and zif268 (Wang et al., 1994) followed by genes of pro-
inflammatory cytokines such as TNF-α and IL-1β (Wang et al., 1994, Liu et al., 1994,
Szaflarski et al., 1995, Saito et al., 1996, Buttini et al., 1996, Uno et al., 1997, I, II). In human
ischemic stroke, the endothelial and perivascular TNF-α immunoreactivity (III), although
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sporadic, overlaps with increased bilateral expression of intercellular adhesion molecule-1
(ICAM-1), which we have previously reported in these infarcted human brains (Lindsberg et
al., 1996b). Indeed, TNF-α production by endothelial and perivascular cells, a phenomenon
also described in rat models of focal and global ischemia (Botchkina et al., 1997, II), might
well be centrally involved in mounting the robust inflammatory cell infiltration reported also
in these infarcted human brains (Lindsberg et al., 1996b). Interestingly, a relationship between
TNF-α immunoreactivity (III) and the inducible form of cyclooxygenase (COX-2; IV), the
key enzyme of prostanoid synthesis, is supported by our studies. The immunoreactivities were
identically detected in neurons and oligoglia during the first day, bilaterally in neurons and
astroglia during days 2 to 3, and detected in invading inflammatory cells from day 3 on.
While significant neuronal COX-2 protein expression was still seen between 8.5 and 18 days
in the hemisphere contralateral to infarction, no neuronal TNF-α was detected after 5.4 days.
Transient neuronal TNF-α induction may have incited the subsequent COX-2 expression,
since pro-inflammatory cytokines are potent inducers of COX-2 (Feng et al., 1995). The
results of this activation cascade would include the release of more proinflammatory
prostanoids with vasoactive effects.
We speculate that the early induction of COX-2 may fuel tissue damage through
prostanoids and free radicals, while the delayed induction in remote brain areas may promote
reconstitutive processes in the face of tissue scarring and remodeling of the surviving neural
networks. Because experimental animal work has suggested production of prostanoids and
free radicals as aggravating tissue injury during cerebral ischemia (Moskowitz et al., 1984,
Stevens and Yaksh, 1988, Baethmann et al., 1989, Farooqui and Horrocks, 1991, Chen et al.,
1995, Nogawa et al., 1997), COX-2 inhibitors may hold out a promise for humans during
acute stroke. However, in view of the inducibility of COX-2 by synaptic activity and its
possible participation in activity-dependent neural plasticity (Yamagata et al., 1993), COX-2
induction observed remotely from the infarct throughout the surviving brain may reflect
global cerebral adaptive and regenerative processes and thus suggest a role for prostanoid
production in the remodeling of neural networks after focal infarction. Indeed, these data
could also be of therapeutic significance in a broad spectrum of human CNS diseases, where
cyclooxygenase activation might play a role, including spinal cord injury (Farooqui and
Horrocks, 1991), HIV-associated dementia (Griffin et al., 1994), and primary degenerative
dementias such as Alzheimer’s disease (Farooqui and Horrocks, 1991, Breitner, 1996,
McGeer et al., 1996, Oka and Takashima, 1997, Chang et al., 1996).
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7.6. Future areas of pathophysiologic and therapeutic research on cytokines in brain
ischemia.
Understanding the role of proinflammatory cytokines in cerebral ischemia is
emerging as discussed earlier. The challenge for the future research of the role of
proinflammatory cytokines in cerebral ischemia is to resolve the intracellular signaling
pathways leading to cell death and inflammation and on the other to repair due to prolonged
expression of the cytokines over days to weeks. The initial proinflammatory cytokine effects
are delayed by hours after cerebral ischemic insult and thus they offer a favorable therapeutic
target also in the clinic. Targeting the intracellular pathways may provide increased
specificity for the neuroprotective intervention. For example, in rats, early inhibition of stress-
activated protein kinase (SAPK) p38 resulted in smaller infarct size, reduced neurological
deficits, and suppression of IL-1β and TNF-α mRNA expression (Barone et al., 2001). P38
activation is induced both by IL-1β and TNF-α and it also induces their synthesis. The
balance between mitogen-activated kinase (MAPK) activation leading to growth and
differentiation and SAP-kinases associated with apoptosis may be crucial in the faith of the
cells (Barone et al., 2001, Skaper and Walsh, 2001). The activation of these kinases is
affected by opposing effects of the proinflammatory cytokines and growth factors, both of
which are induced by ischemia. The induction of growth factors generally follows peak
expression of proinflammatory cytokines and may thus shift the balance towards survival and
recovery (Fig. 17). On the other hand, effects of IL-1β and TNF-α that are delayed by days
are less well understood and their intracellular signaling pathways remain to be elucidated.
Their participation in repair processes may be direct or indirect, for example through
induction of growth factors like IGF-1 or NGF (Skaper and Walsh, 1998, Mason et al., 2001).
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Figure 17. Proposed intracellular signaling pathways of growth factors and proinflammatory
cytokines. Tyrosine kinase A (TrkA) receptor binds its ligang nerve growth factor (NGF). The
neurotrophin and dimerized receptor complex are internalized. This activates ras-dependent
intracellular signaling. The guanosine 5'- triphosphate (GTP)-bound Ras protein binds to the serine-
threonine kinase Raf and initiates a protein kinase cascade that leads to mitogen-activated protein
kinase (MAPK) activation. Activated Raf leads to sequential activation of MEK (MAPK-extracellular
signal-regulated kinase), that in turn activates MAPK. MAPK translocates into the nucleus and
phosphorylates transcription factors such as Elk-1 there, resulting in growth and differentiation. As an
opposing effect, a proinflammatory cytokine bound by its receptor or neurotrophin withdrawal leads to
the activation of stress-induced protein kinases (SAPK). Stimulation of Rac transduction protein leads
to an increase in the activity of SAP kinases p38 and c-jun N-terminal kinase (JNK). Mitogen-activated
protein kinase-activated protein (MAPKAP) kinases are substrates of MAPK. MAPKAP-kinases serve
as a nuclear tarnsporter of p38 (and itself) and thus allow phosphorylation of their substrates in the
cytoplasm. Activating transcription factor-1 (ATF-1) is another substrate of p38. Withdrawal of
neurotrophic factors leading to sustained activation of JNK and p38 has been suggested to precede
apoptosis in neuronal cells. The balance between mitogen-activated kinase (MAPK) activation leading
to growth and differentiation and SAP-kinases associated with apoptosis may be crucial in the faith of
the cells (Skaper and Walsh, 1998, Barone et al, 2001, and Loppnow, 2001).
8. SUMMARY AND CONCLUSIONS
According to our experimental data on rat global forebrain ischemia, neurons in
selectively vulnerable areas for delayed neuronal death may be target cells for ischemia-
induced glial IL-1β effects. The sequential expression of c-fos and TNF-α mRNA supports
participation of c-fos in regulation of TNF-α mRNA expression in striatal and hippocampal
neurons, whereas molecular regulation of TNFR1 gene induction deserves further
investigation. Yet other regulative mechanisms are likely to underlie TNF-α and TNFR1
mRNA regulation in glia, since no upregulation of c-fos gene was detected in the white matter
areas. Corresponding with mRNA changes, an early increase in TNFR1 immunostaining
already after 2 h in somas of large cortical neurons, in activated microglia/macrophages, in
perivascular, and in endothelial cells supports the role of TNF-α as a mediator of ischemic
injury in these cell types. The role of increased immunostaining for TNF-α in
oligodendroglial cells remains to be elucidated.
According to our data on focal ischemic brain infarction in humans, endogenous
TNF-α immunoreactivity is induced bilaterally in multiple types of brain cells up to chronic
phases of ischemia. This response shows partial overlap with TUNEL-depicted dying cells
during the first days of infarct maturation. Even more pronounced and prolonged ischemia-
induced COX-2 immunoreactivity is detected widely in neural cells, and a topographical
evolution of this response evolves over infarct maturation phases from acute to chronic
84
durations of ischemia. Neuronal COX-2 immunoreactivity is detected also in healthy brain
areas besides marked bilateral immunoreactivity in glial and vascular cells. This response
extends beyond HSP immunoreactivity that reflects merely a cellular stress response.
Our results support the usefulness of global ischemia models in identification of
possible mediators of ischemic cell death after focal ischemic insult as well. Based on our
results, histological data derived from experimental ischemia models are also applicable to
human brain infarction, with few precautions. Species differences are evident between the
basal expression of TNF-α and COX-2 mRNA and immunoreactivity. Ischemia-induced
immunoreactivity of these inflammatory mediators was replicated in our human material
respecting the wide array of different cell types described also in the experimental settings. In
contrast, the topography of immunoreactivities for TNF-α and COX-2 involved also the non-
ischemic hemisphere despite focal insult, a phenomenon not investigated (the other
hemisphere used as control) or not evident otherwise in animal models. Additionally, a more
extended expression of these mediators over days and up to two weeks was detected in human
brain infarction in comparison to that in experimental models.
The applicability to human brain of results from experimental interventions on
inflammatory mediators to human brain is a question for future stroke research. Little data is
available to date. At least the salvageable brain area, the penumbra, seems to be smaller in
human brain than in experimental focal ischemia models (Kaufmann et al., 1999, Heiss et al.,
1999, Muir and Grosset, 1999, Ginsberg et al., 1999). The negative results with
neuroprotective agents in clinical stroke underscore the importance of appropriate timing of
treatment(s) and the need for development of brain imaging techniques to reveal pathology
even at the early time-points. Our data support a longer therapeutic window for anti-
inflammatory treatments to limit secondary ischemic brain injury in humans as opposed to
rodents, but offer a warning not to neglect reparative processes by mediators possibly harmful
in the acute phase but taking part in recovery later (i.e. TNF-α and COX-2).
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